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ABSTRACT 
 
Katie Jean Wolfe: Chaperone mediated protective protein aggregation and spatial quality control  
(Under the direction of Douglas Cyr, PhD) 
  
The accumulation of amyloid-like aggregates is a characteristic of protein conformational 
disorders such as Huntington Disease, but whether amyloid-like aggregation is causative or a 
cytoprotective mechanism remains unclear.  Molecular chaperones act as the front line of 
defense against proteotoxicity, as they protect cells by partitioning misfolded proteins towards 
refolding, degradation, or assembly into large benign aggregates.  Herein, a yeast model of 
proteotoxicity was utilized to study cellular mechanisms for protective aggregation.  Ectopic 
expression of polyglutamine (polyQ) expanded Huntingtin (Htt103Q) is toxic in yeast, and 
targeting it to the nucleus enhances toxicity while decreasing SDS-resistant aggregation.  I 
utilized this nuclear Htt103Q as the substrate for a high copy toxicity suppressor screen in yeast 
which identified Sti1 as a molecule that promotes protective aggregation of Htt103Q.  The 
Hsp70 co-chaperone Sti1 regulates spatial quality control of amyloid-like proteins as it induces 
formation of perinuclear foci containing SDS-resistant material.  Accumulation of distinct 
perinuclear foci correlates with suppression of toxicity and increased complex formation with the 
Hsp70/Hsp40 chaperone machinery.  Endogenous Sti1 appears to be a crucial player in a 
chaperone-facilitated protective aggregation pathway, because deletion of Sti1 enhances 
Htt103Q toxicity while decreasing aggregation.  In addition to Sti1, the screen produced a group 
of polyQ-rich proteins, Nab3, Pop2 and Cbk1, as high-copy suppressors of Htt103Q toxicity.  
PolyQ proteins play different roles in Htt103Q toxicity, either to a detrimental outcome where a 
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Q-rich protein is titrated away from its normal function, or beneficially via interactions that 
promote protective aggregation.   Over-expression of Nab3 appears to suppress Htt103Q toxicity 
by replacing a functional pool of Nab3 that was lost to aberrant polyQ interaction.  Over-
expression of Pop2 and Cbk1each suppresses toxicity and promotes aggregation of Htt103Q in a 
slightly different way, but neither can carry out this function in the absence of Sti1.  Therefore, 
Pop2 and Cbk1 act upstream of Sti1 in pathway which promotes protective aggregation of 
amyloid-like assemblies.  These proteins alter the cellular outcome of proteotoxic insult caused 
by Htt103Q by modulating spatial quality control. 
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PREFACE 
 Herein is a compilation of my primary author publications.  Chapter one is a published 
review, chapter two is under review, and chapter three will be submitted following revisions.  
My dissertation work has also included several other projects.  One project was carried out in 
collaboration with the Avrom Caplan lab at the City College of New York which resulted in an 
authorship on a publication about mechanisms of cytosolic protein turnover.  I also contributed 
to another graduate student’s work on chaperone facilitated turnover of short lived cytosolic 
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CHAPTER 1 
Amyloid in neurodegenerative diseases: Friend or foe?1 
 
1.1 Overview 
 Accumulation of amyloid-like aggregates is a hallmark of numerous 
neurodegenerative disorders such as Alzheimer’s and polyglutamine disease.  Yet, 
whether the amyloid inclusions found in these diseases are toxic or cytoprotective 
remains unclear.  Various studies suggest that the toxic culprit in the amyloid folding 
pathway is actually a soluble oligomeric species which might interfere with normal 
cellular function by a multifactorial mechanism including aberrant protein-protein 
interactions.  Molecular chaperones suppress toxicity of amyloidogenic proteins by 
inhibiting aggregation of non-native disease substrates and targeting them for refolding or 
degradation.  Paradoxically, recent studies also suggest a protective action of chaperones 
in their promotion of the assembly of large, tightly packed, benign aggregates that 
sequester toxic protein species. 
1.2 Introduction 
 Protein misfolding and the accumulation of amyloid aggregates are prominent 
features in a vast array of human diseases including numerous neurodegenerative 
disorders [1].  An amyloid fibril is an insoluble, highly ordered aggregate and the major 
component of extracellular plaques found in Alzheimer patient’s brains. Amyloid fibrils 
                                                 
1 Reproduced from Semin Cell Dev Biol, 2011. Jul;22(5):476-81. 
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are defined by a cross- structure where the  sheets run perpendicular to the fibril axis 
[2].  Amyloid can be distinguished from other disordered aggregates by several properties 
including insolubility in ionic detergent, protease resistance, and recognition by 
diagnostic indicator dyes such as Congo Red [3].  Intracellular inclusions which exhibit 
similar characteristics are usually termed amyloid-like [2], but for the purposes of this 
review we will refer to amyloid plaques, fibrils, and amyloid-like aggregates all as 
amyloid unless otherwise noted.  It remains highly controversial whether the amyloid 
deposits found in patients with amyloid disorders is the root problem as researchers first 
thought or if, as increasing evidence suggests, the large inclusions serve a protective 
cellular function [4, 5]. 
Amyloid diseases are associated with a broader family termed protein 
conformational diseases, coined by Carrell and Lomas in 1997.  They proposed that each 
disease occurs via a similar mechanism that involves the abnormal folding and 
aggregation of specific disease associated proteins causing a toxic gain of function [6].  
However, the precise reason behind aggregation of a disease protein causing toxicity 
remains unclear.  An equally challenging enigma in neurodegenerative amyloidoses is the 
cause of selective vulnerability of certain neuronal populations.  Each neurodegenerative 
disorder affects a specific subset of neurons even though the disease associated protein is 
often present in many cells throughout the brain and the rest of the body [7].  This 
phenomenon may be a result of interactions between an array of intracellular factors 
which have both positive and negative influences on the cells ability to buffer 
accumulation of potentially toxic proteins [8, 9].  It has been suggested that subtle 
differences in the expression pattern of broad networks of protein homeostatic factors 
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influence the fate of disease proteins and may account for selective vulnerability [10, 11].  
Yet, the components that make up such collectives of protective or harmful interactions 
remain ambiguous.  Herein, we discuss mechanisms for amyloid toxicity and explore 
how molecular chaperones act to modulate the proteotoxicity associated with formation 
of intracellular amyloid aggregates. 
1.3 Formation of toxic species in amyloid diseases 
Although numerous neurodegenerative diseases are associated with the presence 
of amyloid-like aggregates, the toxic culprit in the aggregation pathway leading to 
amyloid formation remains elusive.  Some researchers suggest that the inclusion bodies 
found in amyloid diseases (bottom, right in Fig 1) are the toxic species [12], yet there is 
often a negative correlation between neurotoxicity and existence of large amyloid 
aggregates[13, 14].  Accumulating literature suggests that a soluble, pre-fibrillar species 
of the disease protein (Soluble Oligomers in Fig 1) causes cytotoxicity and the fibrillar 
aggregates may be part of a cytoprotective mechanism whereby toxic species are 
sequestered [4, 5]. 
How is a normally folded protein converted to a cytotoxic amyloid-like 
conformer?  The conformation of soluble proteins is dynamic.  Native proteins often 
“breath” and sample partially unfolded non-native states which leads to transient folding 
intermediates [15].  The equilibrium between native and non-native conformers is shifted 
toward the non-native state via mutation or upon aging and/or stress [10].  Non-native 
protein conformers are subject to action of protein quality control (PQC) machines and 
are partitioned towards refolding, degradation or aggregation (Fig 1).  The capacity of a 
cell to efficiently manage non-native protein conformers can impact cellular life or death 
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[16].  Although it is clear that directing a natively folded protein towards amyloid 
formation is linked to disease, the exact conformation of the species causing the primary 
toxic insult is still unknown.  There are many neurodegenerative disorders characterized 
by amyloid inclusions, but some of the most highly studied are Alzheimer’s Disease 
(AD) and polyglutamine diseases such as Huntington’s Disease (HD).  Below, we will 
discuss studies directed towards elucidating what the toxic amyloidogenic species might 
be in these two diseases. 
1.3.1 Oligomeric amyloid assembly 
The structural transition from a non-native fold to a pre-fibrillar conformation 
occurs via nucleated polymerization [15, 17].  The nucleation step of this process begins 
very slowly, perhaps due to an unfavorable energy barrier.  After nucleation, however, 
polymerization occurs much more rapidly as the folding intermediate is capable of 
serving as a template or seed for further conformational switching [17].  Interestingly, it 
appears that all proteins which form amyloid may proceed through the same intermediate 
steps [18].  In this section, we will review recent advances in amyloid biology which 
suggest that there are common features in the mechanism for toxicity of structurally 
distinct proteins; these studies also highlight the toxic nature of soluble intermediates in 
the amyloid assembly pathway. 
1.3.1.1 Polyglutamine diseases: Huntington’s Disease    
Polyglutamine (polyQ) diseases are a very well studied, yet enigmatic, subset of 
neurodegenerative disorders.  These diseases are characterized by amyloid inclusions 
where the disease protein contains an expanded polyQ tract [19].  HD occurs when 
Huntingtin (Htt) has a polyQ tract expanded beyond 33 residues.  Disease onset is 
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associated with cleavage of an N-terminal exon 1 fragment containing the expanded 
polyQ tract from Htt.  This is followed by nuclear accumulation of the cleaved fragment 
even though the wildtype form of Htt is localized mainly to the cytosol [20, 21].   
Although aggregation intermediates have been hard to identify, polyQ length 
dependent formation of Htt oligomers has indeed been demonstrated both in vivo and in 
vitro [22, 23].  Indeed, much evidence supports the hypothesis that there may be an 
inverse relationship between Htt toxicity and aggregation.  For instance, expression of Htt 
with an expanded glutamine stretch in cultured striatal neurons causes aggregation in a 
manner that does not correlate with cell death.  In fact, suppression of intranuclear Htt 
inclusion formation is accompanied by increased cell death [14].  While this study 
analyzed a total population of cells, Arrasate et al designed a series of experiments where 
they followed individual neurons.  During the lifetime of the cells, the group tracked 
survival, Htt load, and Htt inclusion formation.  This inventive experimental setup 
revealed that neuronal death correlates with increased polyQ expansion length and 
amount of diffuse Htt within the cell.  Additionally, Htt inclusion body formation reduced 
the amount of soluble Htt thereby increasing neuronal survival [24].  These studies 
provide fundamental insight which supports the idea that the toxic Htt species is soluble 
rather than large intranuclear inclusions. 
1.3.1.2 Alzheimer’s Disease 
Like HD, the formation of amyloid containing plaques was long assumed to be 
the causative agent of neurodegeneration in AD.  However, there are accumulating data 
that suggest that the toxic species is actually a soluble form of the disease causing protein 
[25, 26].  The disease associated protein in AD is amyloid precursor protein (APP).  
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Amyloid aggregation in AD occurs with cleavage of APP fragment into Aβ42 which 
accumulates in extracellular amyloid plaques [27].   Aβ amyloid plaques found in human 
brains of AD patients have a low correlation with severity of AD [28].  A recent study 
using a mouse model of AD strongly supports the toxic oligomeric hypothesis [25].  AD 
symptoms were decreased upon reduction of insulin growth factor signaling which 
correlated with formation of tightly packed A aggregates.  As seems to be the case with 
Htt, Aapparently may undergo oligomerization into a soluble, toxic conformer which 
can be sequestered by protective cellular pathways into larger benign aggregates. 
In AD, the toxic soluble oligomer has been identified in various ways.  Injection 
of medium containing Amonomers and oligomers, but lacking amyloid fibrils, was able 
to inhibit hippocampal long-term potentiation (LTP) in rats [4].  Pretreatment of the 
sample in order to destroy A monomer followed by injection still resulted in decreased 
LTP.  In another in vivo study, rats were injected with an oligomer specific antibody 
which was able to block inhibition of LTP [26].  Altogether, these in vivo results suggest 
that Aoligomers mediate toxicity or nucleate the formation of a toxic protein species.  
Soluble intermediates in the amyloid assembly pathway for Aβ have a structure in 
common with other amyloidogenic proteins as evidenced by a structural specific antibody 
[18].  Importantly, this observation links different amyloid diseases to a common soluble 
amyloid conformation which seems to correlate with toxicity.  Thus, various amyloid 
associated neurodegenerative disorders are apparently caused by a population of harmful 
oligomeric conformers which have common toxic properties.   
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1.3.2 Interaction surfaces of toxic amyloid species 
A broad array of protein interaction partners can affect aggregation both 
positively and negatively, composing a vast protein homeostasis network which needs to 
be balanced to maintain cell viability [10].  For example, aberrant protein-protein 
interactions can interfere with the normal function of various transcription factors, such 
as CREB Binding Protein and TATA Binding Protein, leading to transcriptional 
dysregulation [29, 30].  Htt and various amyloid disease proteins might also deplete 
and/or inactivate other necessary cellular factors.  These include but are not limited to 
ubiquitin proteosome machinery [31], ER associated degradation (ERAD) machinery 
[16], numerous glutamine or glutamine/asparagine (Q/N) rich proteins [32, 33], and large 
proteins predicted to be highly unstructured which may act as hubs or scaffolds [34].  In 
addition, coiled-coil (CC) domains were recently suggested to regulate aggregation and 
toxicity of Q/N rich amyloid proteins [35]. Increased CC propensity in regions of proteins 
that contain polyQ was found to increase occurrence of aggregation and toxicity.  It’s 
possible that the CC structure may be an interaction domain which mediates the 
nucleation event for pre-fibrillar -rich amyloid to occur in polyglutamine diseases.  
Furthermore, there may be distinct chaperone machineries regulating the formation of the 
CC domain, imparting another level of control over the system.  Although we are just 
beginning to understand mechanism for ‘nucleation’ of amyloid assembly, it seems that 
the nature of protein interactions are able to dictate how a non-natively folded protein is 
handled within the cell. 
Yeast prions provide an extremely useful example of interaction surfaces 
affecting nucleation and toxicity of amyloid forming proteins.  Prions are self-
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propagating proteinaceous particles [36] which, in yeast, are amyloid-like heritable 
genetic elements passed from mother to daughter cell [37].  Prion proteins can exist in 
their natively folded conformation or in their amyloid-like prion conformation.  For 
instance, Rnq1 and Sup35 are the proteins which form [RNQ+] (also called [PIN+]) and 
[PSI+] prions, respectively.  The [RNQ+] prion serves as a prime example of a protein 
which affects conformation of another protein.  When [RNQ+] comes into contact with 
another amyloidogenic protein such as Sup35, the prion allows the interaction partner to 
assume its amyloid conformation, in this case [PSI+] [38, 39].  The Rnq1/Sup35 
interaction is normally very weak, but nonetheless Rnq1 can serve as a nucleator of 
amyloid conversion and assembly [40].  In the context of HD, when Htt is expressed in 
yeast, toxicity only occurs in the presence of [RNQ+] [41].  Thus, Rnq1 serves as a 
nucleation factor not only for other yeast prions, but also for other amyloidogenic disease 
associated proteins.  Htt assembly could actually be relocalized to the nucleus by tagging 
Rnq1 with a nuclear localization signal [42].  Relocalizing Htt assembly to the nucleus 
hindered amyloid assembly resulting in the accumulation of a soluble Htt species.  This 
correlated with enhanced Htt-induced cell death.  Consequently, the specific location of 
amyloid conversion impacts cytotoxicity perhaps by influencing aberrant protein-protein 
interactions that might disrupt the essential cellular functions mentioned above. While 
[RNQ+] as well as already templated amyloid proteins can serve as nucleators for 
amyloidogenic proteins, further studies are needed to discover other cellular factors with 
this capability. 
From all of these studies combined, we deduce several things.  First, there seems 
to be a common mechanism of amyloid toxicity even though different disease proteins 
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misfold and aggregate in specific, disease dependent, neuronal subpopulations.  The 
primary amino acid sequence, which is different for each individual disease protein, may 
play a role in selective vulnerability.  Second, the common amyloid toxicity mechanism 
seems to stem from soluble oligomeric species which may be the toxic culprit in various 
neurodegenerative amyloidosis.  Finally, though it remains unclear whether the soluble 
amyloid is a folding intermediate or an off-pathway conformer, the toxic soluble species 
in various amyloid associated neurodegenerative disorders must adopt a -rich structure 
[43, 44].  The toxic -rich structure may expose surfaces amenable to aberrant 
intracellular interactions, but when packaged into large benign aggregates, these surfaces 
may be hidden. 
1.4 Suppression of amyloid proteotoxicity by molecular chaperones 
Molecular chaperones are a crucial part of PQC and work by maintaining the 
proper folding status of proteins within a cell.  Chaperones recognize misfolded 
conformers which are then targeted for refolding, aggregation, or triaged towards 
degradation.  They play a vital role in protecting the cell from conformational diseases 
such as amyloidogenic neurodegenerative disorders.  Chaperones do this by either 
suppressing the initial oligomerization of disease proteins and disassembling disease 
protein aggregates or stimulating the conversion of toxic amyloid assembly intermediates 
into benign aggregates [5, 45-47].  In other words, chaperones can either inhibit or 
promote aggregation but the end goal is to eliminate the toxic soluble species. 
1.4.1 Chaperone dependent suppression of aggregation 
 The Hsp40/Hsp70 system is a well characterized molecular chaperone machine 
that recognizes non-native disease proteins and prevents aberrant aggregation.  Hsp40 
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functions as a co-chaperone by binding non-natively folded proteins and delivering them 
to Hsp70 for refolding [48].  The diversity of Hsp40s polypeptide binding domain 
provides amazing substrate specificity to the Hsp70 [49, 50].  Various Hsp40/Hsp70 
machineries act in different ways towards distinct disease protein substrates.  This 
chaperone machinery has been highly studied as a mechanism which inhibits amyloid-
like aggregate assembly of disease proteins [51, 52].  In yeast, overexpression of Hsp70, 
Ssa1, or Hsp40, Ydj1, alters aggregation of mutant Htt by preventing fibrillization [45].  
Additionally, elevated expression of Ydj1 reduced aggregation and toxicity of Q/N rich 
amyloid aggregates [53].   Likewise in cell culture, increasing the amount of Hsp40 and 
Hsp70 has been shown to decrease formation of polyQ disease protein aggregates as well 
as alleviate toxicity [54, 55].  Thus it seems that the Hsp40/Hsp70 machinery may act to 
hold the disease protein in a soluble conformation in order to prevent accumulation of a 
toxic intermediate or byproduct of the amyloid aggregation pathway. 
Molecular chaperones can also antagonize accumulation of amyloid assemblies 
by acting later in the folding pathway via solubilization of already formed aggregates.  
Hsp104, an AAA ATPase protein remodeling factor in yeast, is required for propagation 
of yeast prions via shearing of large amyloid-like aggregates into smaller seeds [38, 56].  
Utilizing its solubilization activity, overexpression of Hsp104 in a yeast HD model was 
able to effectively fragment amyloid-like aggregates of expanded-polyQ Htt [57].  There 
is no Hsp104 in higher eukaryotes, however, exogenous expression of the chaperone in 
worm and rat models demonstrates that it retains its functional activity.  Expression of 
Hsp104 in C. elegans reduced expanded polyQ protein aggregation and assuaged 
developmental delay [58].  Presence of Hsp104 in rats was also able to suppress toxicity 
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and alter distribution of expanded polyQ proteins [59].  Though these are just a few 
examples, the Hsp40/Hsp70 and Hsp104 machines clearly can protect cells from amyloid 
disease proteins by suppressing aggregation thereby inhibiting formation of a toxic 
soluble species. 
1.4.2 Chaperone mediated aggregation 
 Molecular chaperones are also able to reduce the buildup of toxic oligomeric 
conformers via packaging of these assemblies into larger benign amyloid-like aggregates.  
Work in yeast provides an excellent basis for understanding chaperone mediated amyloid 
assembly.  In a [RNQ+] yeast background, elevation of Rnq1levels results in toxicity [5].  
At normal levels, Rnq1 exists predominately as high molecular weight, SDS insoluble 
species in these studies.  Moderate overexpression of Rnq1 to toxic levels causes 
accumulation of a lower molecular weight, SDS soluble pool.  As in HD and AD, these 
studies suggest that the toxic Rnq1 species might be a smaller soluble species and the 
large SDS insoluble aggregates are a benign product.  Further substantiating this 
hypothesis, co-expression of Rnq1 with the Hsp40 co-chaperone, Sis1, suppressed 
toxicity and promoted Rnq1 assembly into large amyloid-like aggregates [5].  Elevating 
the levels of Rnq1 in a [RNQ+] cell saturates the [RNQ+] biogenesis pathway and results 
in the accumulation of toxic aberrant Rnq1 conformers.  Co-expression of Sis1 may then 
alleviate toxicity by increasing [RNQ+] assembly into large SDS insoluble aggregates.  
Evidence towards this hypothesis also comes from the observation that Sis1 binds 
directly to [RNQ+] specifically in its prion conformation and is required for prion 
propagation [60].  Thus Sis1 acts as a PQC factor to promote aggregation in order to 
prevent accumulation of toxic soluble species of Rnq1 (Letter C in Fig 1). 
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Chaperone machinery has also been shown to promote aggregation of human 
amyloidogenic substrates.  A human Hsp40, Hdj2, has been shown to increase 
aggregation of expanded polyQ Htt in Cos-7 cells [61].  In conjunction with 
Hsp40/Hsp70 machinery, the chaperonin complex, TRiC, also alters amyloid aggregation 
while suppressing polyQ-mediated toxicity as shown in C. elegans [62], yeast [63], and 
cell culture [64].  These studies demonstrate that depletion of TRiC leads to accumulation 
of a toxic, soluble, oligomeric Htt species.  In fact, Behrends et al. utilized size exclusion 
chromatography to show that toxic Htt oligomers exhibited a molecular weight of 
approximately 200 kDa.  TRiC, in conjunction with Ssa1 and Ydj1, was able to shift the 
toxic soluble oligomers into non-toxic 500 kDa aggregates [63].  Thus, promotion of 
protective aggregation seems to be a mechanism whereby cells eliminate cytotoxic pools 
of Htt oligomer.  Altogether, these studies demonstrate that molecular chaperones protect 
cells from proteotoxic insult by targeting misfolded proteins away from toxic oligomeric 
states; chaperones either enhance assembly into fibrillar benign aggregates, or 
disassemble the oligomers into soluble monomeric forms which can be properly folded 
[65].  Incredibly, chaperones are able to carry out these opposing activities, both of which 
lead to promotion of a healthy and functional folding state of non-native proteins in the 
cellular milieu.   
1.4.3 Chaperone assisted protein degradation 
 Chaperones also mediate clearance of proteotoxic substrates via degradation of 
non-native proteins.  When molecular chaperones cannot repair a misfolded protein, it 
can be targeted for degradation either via the ubiquitin proteosome system or autophagy.  
CHIP (carboxy terminus of Hsc70-interactin protein) is an E3 ligase which mediates 
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transfer of polyubiquitin chains to misfolded substrates, but also has inherent chaperone 
activity and acts as an Hsp70/Hsc70 co-chaperone [66, 67].  Indeed, CHIP has been 
shown to play a role in chaperone mediated degradation of expanded polyQ disease 
proteins.  When CHIP was overexpressed, ubiquitination and turnover of polyQ disease 
substrates such as Htt increased, resulting in suppression of polyQ aggregation and cell 
death [68, 69].  CHIP’s chaperone activity is necessary in order to observe this 
suppression. Elevated Hsc70 levels increased CHIP’s ability to suppress aggregation and 
cell death, thus CHIP works cooperatively with Hsc70. 
 Autophagy is another cellular clearance mechanism for neurodegenerative 
amyloid proteins which is independent of the ubiquitin-proteosome system.  Autophagy, 
literally meaning “self-eating”, is a cellular process that involves compartmentalizing 
bulk cytosol, including cell components and proteins, which is sent to lysosomes to be 
degraded [70].  When autophagy was suppressed in mice via inhibition of ATG5, even 
without the presence of disease causing proteins, the mice displayed characteristics of 
neurodegeneration [71]. As a result, this study suggests that neuronal cells are constantly 
challenged by the formation of misfolded proteins and autophagy is required for the 
removal of these proteins. In the absence of this pathway, misfolded proteins accumulate 
and disrupt normal cellular function.  In the context of neurodegenerative diseases, 
expanded polyQ disease proteins have indeed been shown to be degraded via autophagy 
[72].  Furthermore, recent evidence suggests that mutant Htt can specifically be targeted 
to autophagosomes by acetylation [73].  Altogether, these studies establish that 
degradation, which can also be chaperone mediated, is a crucial mechanism by which 
neurodegenerative disease associated proteins are cleared from the cell.   
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1.5 Concluding Remarks 
Normal PQC is crucial to cell viability because it maintains the balance of non-
native proteins targeted towards refolding or degradation.  A shift in this equilibrium can 
be highly detrimental to the cell, leading to death.  Specific mechanisms of proteotoxicity 
caused by misfolded protein accumulation remain unclear, but many cellular processes 
have been implicated.  Neurodegenerative disorders characterized by amyloid inclusions 
seem to be caused by a multifactorial mechanism which may be centered around titration 
and inactivation of essential cellular components in processes such as transcription [74], 
degradation via the ubiquitin proteosome [31], and ER associated degradation (ERAD) 
[16] among others.  Aberrant interactions arising from exposed hydrophobic surfaces 
within the amyloidogenic disease protein [33, 75] and/or mislocalization [42] can lead to 
cell death. 
  Not all cell types are equally affected by a single amyloidogenic protein, 
however.  The equilibrium between a native and non-native conformation is cell type 
specific, and not all cell types equally respond to the same protein misfolding event.   
Some cell types may be less equipped than others and therefore unable to clear toxic 
amyloid species.  Cellular mechanisms for clearance of these toxic amyloid species 
include chaperone dependent suppression or promotion of aggregation, chaperone 
dependent turnover, and clearance via autophagy. 
Although chaperone machinery can partition misfolded proteins between these 
various pathways, some proteins are able to escape normal PQC mechanisms and cause 
havoc within the cell.  By gaining a better understanding of the affinities of non-native 
proteins for chaperones versus their propensity to aggregate, we may shed light upon 
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exactly how those proteins can escape PQC machinery.  Cellular environment seems to 
play a major role here.  Upon cellular stress, it has been well documented that the 
environment within the cell shifts in order to avoid accumulation of misfolded protein 
species.  Over time, these PQC pathways become less efficient.  If the balance between 
refolding, degradation, and protective aggregation pathways is jeopardized then cytotoxic 
protein conformers are able to accumulate.  Specific cell types may or may not be unable 
to respond accordingly by upregulating an alternative pathway to compensate for the 
stress.  Thus, future research in the realm of amyloid diseases should focus on defining 
the protein networks within cells that help protect against that fate.  In the long term, 
identification of protective cellular factors and how these networks are integrated and 
regulated will help us better understand exactly how amyloid causes disease. 
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1.6 Figures 
 
 
 
 
Figure 1.1 Protein folding and amyloid formation.  
Non-native proteins can be partitioned into several conformational fates including 
refolding, ordered or disordered aggregate formation, and degradation.  Amyloid is a type 
of very structured (or ordered) aggregate and forms through a poorly understood 
pathway.  Sometimes a protein comes into contact with another surface that influences 
how it folds, but exactly how this occurs remains unclear.  This interaction could be 
called nucleation since the newly “templated” monomer can now influence other 
monomers to adopt the same conformation.  Following nucleation, possible small 
oligomeric species or amyloidogenic aggregates can assemble although the structure of 
this species is unknown.  Molecular chaperones act at various points in the amyloid 
formation pathway to influence how the non-native protein is handled, as designated with 
letters A-C. 
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CHAPTER 2 
The Hsp70/90 co-chaperone, Sti1, suppresses proteotoxicity by regulating spatial 
quality control of amyloid-like proteins2 
 
2.1 Overview 
Conformational diseases are associated with the conversion of normal proteins 
into aggregation prone toxic conformers with structures similar to -amyloid.  Spatial 
distribution of amyloid-like proteins into intracellular quality control centers can be 
beneficial, but cellular mechanisms for protective aggregation remain unclear.  A high-
copy suppressor screen in yeast was utilized to identify roles for the Hsp70 system in 
organization of toxic polyglutamine expanded Huntingtin (Htt103Q) into benign 
assemblies.  The TPR-repeat co-chaperone Sti1 is reported to mediate the spatial 
organization of Htt103Q-GFP into benign foci.  Under toxic conditions, Htt103Q 
accumulates in unassembled states and speckled cytosolic foci.  Subtle modulation of 
Sti1 activity reciprocally impacts Htt toxicity and the packaging of Htt103Q into foci.  
Loss of Sti1 exacerbates Htt toxicity and hinders foci formation, whereas elevation of 
Sti1 suppresses Htt toxicity while organizing small Htt103Q foci into larger assemblies.  
Sti1 also suppresses cytotoxicity of the glutamine-rich yeast prion [RNQ+] while 
reorganizing speckled Rnq1-mRFP into distinct foci.  Htt103Q and Rnq1 are normally 
detected in peripheral IPOD compartments, and Sti1 inducible foci (StiF) are unique 
because they are perinuclear and do not colocalize with the aggresome.  Sti1 aids in 
                                                 
2 A revised version of this chapter has been accepted for publication at Molecular Biology of the Cell 
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suppression of proteotoxicity by redirecting amyloid-like proteins to accumulate in the 
StiF. 
2.2 Introduction 
Protein conformational diseases represent a collection of disorders in which 
structurally diverse  proteins are converted to a common cytotoxic conformational state 
that has features of -amyloid [1]. A large number of normal proteins are converted to an 
amyloid-like state that is rich in -structure, detergent insoluble, and binds indicator dyes 
such as thioflavin-T [2].  -amyloid is deposited in extracellular plaques in the brains of 
Alzheimer’s patients [2-4], and there are also numerous instances where protein 
conformational disease is associated with intracellular accumulation of amyloid-like 
assemblies [1].  Flux of proteins through the amyloid assembly pathway is associated 
with disease, but whether the amyloid-like aggregates themselves or small oligomers of 
converted proteins are toxic is debatable [5-7].  There is mounting evidence that 
molecular chaperones facilitate the packaging of toxic protein species into protein 
handling depots to suppress proteotoxicity [8, 9].  Yet, the cellular mechanisms for 
molecular chaperone function in protective protein aggregation remain unclear. 
Hsp70 functions with specialized co-chaperones to suppress protein aggregation, 
refold clients, and promote protein degradation [10-13].  Hsp70 binds extended regions of 
polypeptide chains in an ATP-dependent reaction cycle that is regulated by Hsp40 [14-
16].  Hsp40 serves as a substrate selector and helps stabilize Hsp70:polypeptide 
complexes by converting Hsp70-ATP to Hsp70-ADP.  Substrate release from Hsp70 is 
regulated by nucleotide exchange factors and tetratricopeptide repeat (TPR) co-
chaperones [17-19]. TPR co-chaperones contain a TPR repeat which serves as an 
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Hsp70/Hsp90 interaction domain that recognizes a conserved C-terminal EEVD motif 
[17], and specialized functional domains that dictate the fate of chaperone bound clients.  
Several examples of this are as follows: Sti1, whose mammalian homologue is HOP, 
contains 3 separate TPR domains which organize Hsp70 and Hsp90 into complexes and 
permit sequential action of these chaperones upon clients such as kinases and hormone 
receptors [20]; Sti1 also functions with Hsp70 and Hsp40 to modulate the biogenesis and 
function of prions in yeast and humans [21-23] ; CyP40 contains a cis-trans-prolyl-
isomerase domain that facilitates conformational maturation of late stage protein folding 
intermediates [24]; CHIP is an ubiquitin ligase that regulates the heat stress response [25, 
26] and targets misfolded proteins for proteasomal degradation [13, 27].  Thus, TPR-
repeat co-chaperones of Hsp70/Hsp90 act downstream of Hsp40s and participate in 
multiple aspects of protein homeostasis. 
In protein aggregates, hydrophobic surfaces that would be recognized by 
components of the Hsp70 system are buried, so they escape recognition by protein quality 
control machines.  Thus, aggregates are inefficiently cleared from cells and cause 
cytotoxicity by damaging cell membranes, altering the conformation of other proteins and 
sequestering essential cellular proteins [4, 28, 29].  Aberrant proteins that are not initially 
cleared from the cytosol can be segregated into distinct cytosolic foci, observed in both 
yeast and mammalian systems, that appear to store oligomers and aggregates until 
conditions favor refolding or degradation [30-38].  Remarkably, detergent soluble and 
amyloid-like protein conformers are segregated into different protein handling depots, 
and this process is influenced by components in the Hsp70 system [8, 34, 36, 39]. 
Amyloid-like and detergent insoluble protein assemblies accumulate in perinuclear 
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aggresomes [31, 38], and insoluble protein deposits (IPOD), which are located in the cell 
periphery [30, 37]. Protein oligomers and aggregates that are soluble in detergents 
accumulate in the spatially distinct juxtanuclear quality control (JUNQ) [30, 33] and 
peripheral compartments [32].  Ubiquitinated proteins that evade the proteasome and 
terminally misfolded proteins that escape recognition by protein quality control (PQC) E3 
ligases are swept into the JUNQ [30].  Proteins in the JUNQ can be solubilized and 
degraded by the proteasome in a pathway that involves the PQC E3 ligase Ubr1 [34].  
The peripheral compartment contains Hsp42, and holds proteins in a folding competent 
state [32].  The IPOD may function in protein disaggregation of detergent insoluble 
aggregates [37] whereas the peripherial compartment and JUNQ aid in refolding [32] and 
degradation [30] of detergent soluble protein assemblies, respectively. The aggresome 
resembles an inclusion body and may represent a long-term storage site for aberrant 
proteins [31, 38].  Thus, cells have the capacity to sequester potentially toxic protein 
species, but the mechanism for spatial segregation of protein handling centers is a 
mystery. 
Although flux through protein aggregation pathways is associated with cell death, 
chaperone dependent sequestration of amyloid-like proteins into protein handling centers 
correlates with suppression of proteotoxicity [3, 6, 8, 40].  In yeast models, 
overexpression of the yeast prion protein Rnq1 is toxic, but only if preexisting [RNQ+] 
prions are present to seed its conversion to an amyloid-like conformation [8, 41, 42].  The 
Hsp70, Ssa1, cooperates with the Hsp40, Sis1, to increase the efficiency by which seeded 
forms of Rnq1 assemble into amyloid-like [RNQ+] prions and thereby suppress 
proteotoxicity [8].  Interestingly, a fragment of Huntingtin (Htt) similar to those found in 
 28
inclusions from Huntington’s Disease brains (Htt103Q), is toxic when expressed 
ectopically in yeast, but only if [RNQ+] prions are present [43].  In yeast, the aggregation 
state of Htt103Q and its toxicity are inversely correlated with very tight, detergent 
insoluble aggregates being benign and loose, detergent soluble aggregates being toxic 
[44].  Aggregation and toxicity of Htt103Q is influenced by its subcellular environment 
and also by the sequences of amino acids that flank its polyQ stretch [39, 44, 45].  Forms 
of Htt103Q that contain the polyproline region which follows the polyQ domain in full 
length Htt are benign due to their sequestration into the aggresome in a process that 
requires the ringed molecular chaperone p97 [38].  Forms of Htt103Q which lack the 
polyproline region are toxic as they accumulate in loose aggregates that are distributed 
throughout the cytosol in speckled foci, and tight aggregates that accumulate in the IPOD 
[30, 39].  Thus, studies of proteotoxicity of Htt103Q and Rnq1 in yeast provide an 
excellent model system to uncover mechanisms for Hsp70 function in protein 
detoxification through protective protein aggregation. 
Herein we uncovered a role for the co-chaperone Sti1 in orchestrating spatial 
organization of Htt103Q and Rnq1 into benign amyloid-like assemblies. We employed 
the toxic form of Htt103Q lacking the proline-rich region and screened for proteins that 
suppressed proteotoxicity by facilitating its aggregation.  Sti1 cooperates with the Hsp70 
system to control the spatial organization of amyloid-like protein assemblies, thereby 
suppressing proteotoxicity.  Sti1 interacts with Hsp70 to redirect Htt103Q away from the 
IPOD and other cytosolic protein deposition sites and induce accumulation of amyloid-
like protein species into protective perinuclear foci.  Sti1 functions as a central 
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coordinator of spatial PQC to organize molecular chaperone assemblies with their 
substrates as to drive protective aggregation of amyloidogenic proteins.   
2.3 Results 
2.3.1 The Hsp70/Hsp90 co-chaperone Sti1 suppresses Htt103Q toxicity 
In order to identify cellular factors that defend against proteotoxicity, we carried 
out a high copy screen in Saccharomyces cerevisiae to discover proteins that suppressed 
Htt103Q toxicity.  A construct encoding the first 17 amino acids of the Htt gene followed 
by 103 glutamines and a GFP moiety (Htt103Q) was integrated into a W303 strain 
under control of the galactose promoter.  Htt103Q expression caused a growth defect in a 
glutamine length dependent manner [43] [44], and differential sensitivity to Htt103Q was 
exhibited by individual strains (Figure 2.1A).  The yeast Hsp70/Hsp90 co-chaperone Sti1 
[46] was identified as a high copy suppressor of the severe Htt103Q dependent growth 
defect.  Expression of another TPR family co-chaperone, Sgt2, did not suppress Htt103Q 
toxicity (Figure 2.2A) indicating this activity is not a characteristic of TPR proteins in 
general.  Additionally, deletion of Sti1 caused Htt103Q to be toxic in a strain where it 
was normally benign (Figure 2.1A right panels).  Parallel growth assays using wildtype 
and Sti1 Htt25Q strains demonstrate that this phenotype was not due to reduced growth 
on galactose (Figure 2.1A left panels).   
Elevation of Sti1 caused the subcellular localization of Htt103Q to become 
redistributed from a mixture of diffuse material and foci that are dispersed throughout the 
cytosol to several distinct large foci that were often found in close proximity to the 
nucleus (Figure 2.1B).  Conversely, deletion of Sti1 greatly reduced Htt103Q punctae 
formation, with the majority of Htt dispersed in a diffuse cytosolic pattern (Figure 2.1B).  
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Sti1 overexpression had no effect upon Htt103Q levels, yet deletion reduced expression 
(Figure 2.1C), likely due to delayed induction from the galactose promoter [47].  Deletion 
of Sti1 clearly sensitizes the cell to Htt103Q because even though there was reduced 
Htt103Q expression, the growth defect was exacerbated. 
Sti1 may suppress Htt103Q toxicity by organizing it into foci, however, fewer 
foci may be observed in the Sti1 strain since there is less Htt103Q being expressed.  To 
rule out this possibility, Htt103Q-GFP localization was examined when expressed to 
equivalent levels via copper inducible promoter in wildtype and Sti1 strains (Figure 
2.1D).  Again Sti1 was required for efficient organization of Htt103Q into foci.  We also 
examined the influence of Sti1 expression upon temporal aspects of Htt103Q foci 
accumulation.  Over a 4 hour time course, Sti1 accelerated Htt103Q foci formation while 
reducing number of foci per cell (Figure 2.2B).  Cycloheximide chase experiments 
demonstrate that once formed, the Sti1 dependent foci containing Htt103Q were stable 
for at least 5 hours (Figure 2.2C).  These data provide a correlation between Sti1 action in 
suppression of Htt toxicity and the packaging of Htt103Q into perinuclear foci. 
Does Sti1 act only on Htt103Q, or can it also modulate the organization of other 
cytosolic protein aggregates?  To answer this question, we utilized mCitrine tagged 
luciferase, an Hsp70 client which aggregates during heat stress [32].  At 30°C, mCitrine-
luciferase is diffuse throughout the cytosol and was not impacted by Sti1 overexpression 
(Figure 2.1E, top panels).  During thermal stress at 42°C for 20 minutes, luciferase 
accumulated in numerous aggregates throughout the cytosol.  Neither elevation nor 
deletion of Sti1 changed the appearance of the luciferase aggregates (Figure 2.1E, bottom 
panels).  Thus, since Sti1 does not suppress aggregation of heat-damaged luciferase or 
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organize aggregated luciferase into foci, it appears to act specifically on aggregated forms 
of Htt103Q. 
The TPR co-chaperone CHIP inhibits Hsp70 function in protein folding [27], so it 
is possible that Sti1 impacts Htt103Q assembly into foci by similarly interfering with 
Hsp70.  This is unlikely, because Sti1 overexpression does not cause mCitrine-luciferase 
to aggregate (Figure 2.1E).  Nevertheless, we examined in the impact of purified Sti1 on 
the ability of Ssa1 and Sis1 to refold denatured luciferase and found that Sti1 has no 
effect (Figure 2.2, D and E).  Elevation of Sti1 does not appear to cause a change in 
Htt103Q aggregation by inhibition of normal Hsp70 folding activity.  
 If Sti1 has a direct effect upon Htt103Q, it should be present with Htt103Q foci.  
When expressed alone, Sti1 tagged with a monomeric RFP (mRFP) exhibited a diffuse 
localization pattern in the cytosol (Figure 2.1F).  When co-expressed with Htt103Q, it 
redistributed the polyQ protein into distinct punctae, and Sti1-mRFP was indeed 
concentrated in foci with Htt103Q (Figure 2.1F, arrows).   These data demonstrate that 
Sti1 promotes Htt103Q foci formation and this is beneficial to the cell, so there is an 
inverse relationship between Htt103Q aggregation and toxicity that is modulated by Sti1. 
2.3.2 Sti1 interacts with high molecular weight forms of Htt103Q 
To understand the mechanism for Sti1 action, we asked if it interacted with 
unassembled low molecular weight Htt103Q monomers or high molecular weight 
oligomeric assemblies.  Therefore, we analyzed the elution patterns of Sti1 and Htt103Q 
on a Sephacryl S200 gel filtration column.  Cell lysates prepared by homogenizing 
spheroplasts in the absence of detergent were immediately applied to the gel filtration 
column.  Every third fraction collected was run on an SDS-PAGE gel and probed by 
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Western blot for levels of Htt103Q and Sti1 (Figure 2.3A-C).  A portion of high 
molecular weight SDS-resistant Htt103Q is retained at the stacking front of the gel [39], 
so both the stacking and running gel sections are shown.  Htt expression was similar in 
the presence of endogenous and overexpressed Sti1 (Figure 2.1C) and under all 
conditions, a pool of Sti1 (molecular weight of 67.6 KDa) migrated as a dimer [48] 
(Figure 2.3A).  In addition to the dimeric form, endogenous Sti1 co-migrated with high 
molecular weight forms of Htt103Q.  Yet, Htt103Q did not co-migrate in the fractions 
where the dimeric form of Sti1 was present (Figure 2.3A top panel/control).  Importantly, 
endogenous Sti1 did not migrate in a high molecular weight fraction when non-
aggregation prone Htt25Q was expressed (Figure 2.3A bottom panel).  Upon 
overexpression of Sti1, the high molecular weight pools of Sti1 and Htt103Q both 
increased proportionally (Figure 2.3A top panel/+Sti1, and 2.3C), yet this was not 
observed when Sti1 levels were elevated in the presence of Htt25Q (Figure 2.3A bottom 
panel/+Sti1).  Sti1 was also present in immune complexes when high molecular weight 
Htt103Q was precipitated from column fraction 12, (Figure 2.3B).  This interaction was 
specific because there was no Sti1 signal detected in the absence of Htt103Q (Figure 
2.3B).  While reorganizing foci and suppressing toxicity, Sti1 appears to interact with 
high molecular weight forms of Htt103Q. 
2.3.3 Sti1 modulates assembly of amyloidogenic substrates at a perinuclear location 
Htt103Q is toxic to yeast upon undergoing a conformational change driven by 
interaction with the [RNQ+] prion [42, 43].  [RNQ+] prion biogenesis and toxicity is 
modulated by Hsp70 and Hsp40 [8, 49-51] and weak variants of the prion [PSI+] are 
eliminated from yeast by elevation of Sti1 activity [52].  Thus, the impact of Sti1 on 
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[RNQ+] prion toxicity and subcellular organization was evaluated.  Just as with Htt103Q, 
an increase in Sti1 suppressed the toxicity associated with Rnq1 overexpression (Figure 
2.4A).  Under conditions utilized, Rnq1 expression is highly toxic, so deletion of Sti1 
only led to a modest increase in growth defects caused by Rnq1 overexpression (Figure 
2.4B).  At endogenous levels of Sti1, Rnq1-mRFP foci were speckled throughout the 
cytosol, but upon overexpression of Sti1, Rnq1-mRFP became localized to one or two 
distinct juxtanuclear foci (Figure 2.4C).  In contrast to what is observed with Htt103Q-
GFP, speckled Rnq1-mRFP foci were still detected in a Sti1 strain indicating that this 
strain remains in the [RNQ+] prion state (Figure 2.4C, Sti1).  Sti1 is not required for 
maintenance of [RNQ+] prions and Sti1 overexpression does not eliminate [RNQ+] 
prions.  Instead, suppression of Rnq1 and Htt103Q toxicity by Sti1 is associated with 
reorganization of multiple punctae containing these proteins into one or two distinct 
perinuclear foci.   
We next sought to determine what conformational state of Rnq1 and Htt103Q is 
favored under conditions where Sti1 suppresses their proteotoxicty.  Sti1 increased 
accumulation of oliogmeric SDS-resistant forms of Rnq1 and Htt103Q by more than two-
fold (Figure 2.5A).  Deletion of Sti1 reduced Htt103Q SDS-resistant material by over 
50% while there was little effect upon Rnq1 (Figure 2.5A).  Sti1 appears to act on the 
oligomeric assemblies of Htt and Rnq1 that only form in [RNQ+] prion strains because 
its overexpression has no effect upon localization of Htt103Q or Rnq1 in [rnq-] strains 
(Figure 2.5B).   
Conversion to an SDS-resistant oligomer is a characteristic of amyloid, so Sti1 
appears to target amyloid-like forms of proteins to perinuclear foci. To gain experimental 
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support for this conclusion, we asked if Sti1 inducible foci stain positive for the amyloid 
specific dye thioflavin-T [2].  Rnq1-mRFP was used as a tool instead of Htt103Q-GFP 
because, upon binding amyloid, thioflavin-T emission is enhanced to a wavelength in the 
excitation range of GFP [53].  [RNQ+] prions have features of amyloid-like protein 
species as they bind thioflavin-T, whereas the dye does not bind to amorphous aggregates 
of Rnq1 that accumulate in a [rnq-] strain [8]. Speckled Rnq1-mRFP foci in both the cell 
periphery and in a perinuclear location were positive for thioflavin-T staining, as were the 
perinuclear Sti1 induced Rnq1-mRFP foci (Figure 2.5C).   
To ascertain whether Htt103Q is also present in foci with amyloid-like [RNQ+] 
prions, we asked if they co-localize with each other in the presence and absence of Sti1 
overexpression (Figure 2.5D).  When Htt103Q-GFP and Rnq1-mRFP were co-expressed, 
a mixed population of speckled foci was detected with approximately 20% of foci 
containing both proteins (Figure 2.5D, inset and arrows).  Sti1 elevation resulted in 
redistribution of most of the Htt103Q and Rnq1 to one or two larger perinuclear foci that 
contain both proteins (Figure 2.5D).  
Due to the co-localization of Htt103Q and Rnq1 in foci that contain amyloid-like 
proteins, we asked if Sti1 is necessary for these proteins to interact.  In order to answer 
this question, we took advantage of the fact that addition of a nuclear localization signal 
(NLS) to Rnq1 directs [RNQ+] prions to the nucleus and Htt103Q follows [39].  Thus, if 
Sti1 is required for interaction between Htt103Q and Rnq1, deletion of Sti1 would 
prevent this relocalization.   However, Rnq1-NLS still redistributed Htt103Q to the 
nucleus in both the presence and absence of Sti1 (Figure 2.6A).  Thus, Sti1 promotes 
accumulation of Htt103Q and foci that contain amyloid-like species of Rnq1, but does 
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not appear to be necessary for Rnq1 and Htt to interact.  Instead, Sti1 may control the 
spatial organization of amyloid-like proteins into different protein handling centers. 
2.3.4 Sti1 inducible foci are distinct protein quality control depots 
Sti1 inducible foci (StiF) are perinuclear and contain amyloid-like material, thus 
are distinct from the IPOD and JUNQ.  To characterize the StiF in more detail, we 
determined whether these foci contain PQC machinery which would help protect cells 
from proteotoxic stress.  At endogenous levels of Sti1, Hsp104 and Hsp42 were not 
detected in foci which contained Htt103Q-GFP (Figure 2.7, A and B).  Yet, while 
Htt103Q-GFP and Hsp104 co-localized in the StiF (Figure 2.7A), Hsp42 was not 
typically present (Figure 2.7B).   
Since the StiF is an Hsp104 positive inclusion, we next determined if StiF 
formation is impacted by modulation of Hsp104 activity.  Here, we treated cells 
containing endogenous or overexpressed Sti1 with guanidinium hydrochloride (GndHCl)  
for 4 hrs to inhibit Hsp104 activity [54, 55], and the effect this had on organization of 
Rnq1-mRFP into foci was monitored. To determine the nature of the foci observed, we 
employed strains containing a GFP tagged version of Hsp42 or Spc42, a spindle pole 
body component which marks the aggresome [31], which were under control of their 
endogenous promoter.  Hsp104 inhibition condensed most of the Rnq1-mRFP material to 
one peripherally localized puncta, which co-localized with Hsp42, but not with Spc42 
(Figure 2.7, C and D).  Foci formed during Sti1 overexpression in the untreated samples 
did not co-localize with Spc42 revealing that the StiF is not the aggresome (Figure 2.7C).  
Furthermore, Htt103Q-GFP containing the proline-rich region is targeted in a p97 
dependent manner to aggresomes [38] and deletion of Sti1 has no effect on aggregation 
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of Htt103Q-Pro (Figure 2.6B).  Therefore, Sti1 is not promoting the accumulation of 
Htt103Q in the yeast aggresome.  
Strikingly, Sti1 appears to divert proteins from the IPOD and promote their 
accumulation in the StiF, a previously unidentified protein handling depot.  Rnq1 is 
considered to be an IPOD marker [30, 37] and the single Hsp42-GFP containing 
peripheral foci detected when Hsp104 is inhibited for 2 hrs appears to be the IPOD 
(Figure 2.7, C and D). Elevation of Sti1 in the presence of GndHCl prevents Rnq1-mRFP 
from accumulating in a peripheral foci and instead promotes its accumulation in the StiF. 
These data demonstrate that organization of Rnq1 in speckled foci is highly 
sensitive to activity of Hsp104 and the Hsp70 system.  Impairment of Hsp104 leads 
Rnq1-mRFP to accumulate in cytosolic foci.  The effects of Sti1 on Rnq1-mRFP foci 
resemble those of Hsp104, except Sti1 promotes accumulation of amyloid-like proteins in 
StiF rather than a peripheral puncta.  The StiF is a novel perinuclear quality control depot 
that contains Sti1, Hsp104, and amyloid-like proteins.  It appears to be distinct from the 
aggresome as it does not form at the spindle pole body [38] and may serve as a 
detoxification center for amyloid-like proteins. 
2.3.5 Sti1 reorganizes complexes that contain Htt103Q and Hsp70 
Sti1 associates with oligomeric forms of Htt103Q (Figure 2.3) and co-localizes 
with amyloid-like proteins in the StiF (Figure 2.5), which might enable it to suppress Htt 
toxicity by acting alone or in concert with Hsp70/Hsp90. The co-chaperone function of 
Sti1 is conferred by three TPR repeats which are important for interaction with Hsp70 
and Hsp90 (Figure 2.8A).  TPR1 is implicated in interaction with Hsp70, and TPR2a with 
Hsp90, while both chaperones bind with lower affinity to the TPR2b region [20, 56, 57].  
 37
Hence, point mutations in respective TPR domains were constructed and the ability of 
different TPR mutants to suppress Htt103Q toxicity and promote StiF formation was 
evaluated (Figure 2.8B).  While mutations in TPR2a and TPR2b had no effect (Figure 
2.8, B-D), mutations in TPR1 hindered the ability of Sti1 to redistribute Htt103Q to the 
StiF (Figure 2.8D).  TPR1 mutants also lost their ability to suppress the Htt103Q growth 
defect (Figure 2.8B).  Thus, StiF formation and suppression of Htt103Q toxicity requires 
functional domains of Sti1 that enable it to interact with the Hsp70/Hsp90 system. 
To determine the impact Sti1 has upon interactions between Hsp70 and Hsp90 
with Htt103Q, complex formation between these proteins was evaluated by co-
immuneprecipation (coIP) (Figure 2.8, E and F).  Htt103Q was immuneprecipitated from 
yeast lysates prepared under non-denaturing conditions, and the presence of Ssa1, Hsp90, 
Ydj1, Sis1, and Sse1 in precipitates was determined by western blot.  Entrance of Sti1 
into complexes altered relative quantities of different molecular chaperones that 
associated with Htt103Q (Figure 2.8, E and F).  The influence of Sti1 on Hsp70/Hsp90 
interactions with Htt103Q was sensitive to changes in nucleotide level and appeared to 
result from ATP dependent chaperone:substrate interactions (Figure 2.8E).  Interestingly, 
Sti1 increased levels of Ssa1’s cognate Hsp40, Sis1, by around 4-fold and Ssa1 by over 
2-fold (Figure 2.8, E and F).  In contrast, little of an alternative Hsp40, Ydj1, was present 
and Sti1 reduced the amount of co-precipitated Hsp90 and Sse1.  These collective data 
indicate that spatial quality control of amyloid-like assemblies involves Sti1 dependent 
reorganization of complexes containing Hsp70 and Htt103Q with the greatest effect 
being a dramatic increase in the presence of Sis1.   
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2.3.6 Sti1 and Sis1 cooperate to modulate amyloid toxicity 
Sis1 interacts with oligomeric forms of Rnq1 to facilitate the propagation and 
impact the spatial organization of [RNQ+] prions [39, 49, 50].  Thus, Sti1 and Sis1 may 
cooperate to suppress growth defects caused by the presence of amyloid-like protein in 
the cytosol.  We therefore investigated whether or not Sti1 is required for Sis1 to suppress 
Rnq1 and Htt103Q toxicity (Figure 2.9, A and B).  Elevation of Sis1 diminished Rnq1 
toxicity in a wild type strain, but its protective effect was severely diminished in a Sti1 
strain, even though deletion of Sti1 had no effect on Sis1 expression.  Similarly, elevated 
Sis1 also suppressed the growth defect caused by Htt103Q, and this protective effect was 
reduced in a Sti1 strain (Figure 2.9B).  
Further support for functional interaction between Sti1 and Sis1 in buffering the 
toxicity of amyloid-like proteins comes from the demonstration that Sti1 drives the 
redistribution of Sis1 to the StiF (Figure 2.9C).  Under normal conditions, Rnq1-mRFP 
was found in speckled foci and Sis1-GFP was distributed between the cytosol and 
nucleus (Figure 2.9C and [39]).  Upon elevation of Sti1, the localization pattern of Sis1 
changed dramatically and a large pool of it was concentrated in the StiF with Rnq1-
mRFP (Figure 2.9B).  Data presented in Figure 2.7-2.9 suggests that Sti1 helps suppress 
proteotoxicity via stabilization of complexes between Hsp70, Sis1, and amyloid-like 
protein assemblies to promote their accumulation in the perinuclear StiF. 
2.4 Discussion 
The Hsp70/90 co-chaperone, Sti1, suppresses proteotoxicity by reorganizing 
amyloid-like assemblies into the StiF, a novel protein handling depot.  The StiF is a 
juxtanuclear compartment containing thioflavin-T positive assemblies of Rnq1 and 
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templated Htt103Q.  Amyloid-like protein accumulation in the StiF correlates with 
suppression of proteotoxicity caused by Rnq1 and Htt103Q.  Partitioning of aberrant 
proteins between the StiF and other protein handling centers is controlled by interactions 
between Sti1 and the Hsp70 chaperone system.  Loss of Sti1 exacerbates Htt 
proteotoxicity while increases in Sti1 levels suppress it by increasing protein 
accumulation in the StiF.  Sti1 is identified as an important component of the 
Hsp70/Hsp90 system that acts in spatial PQC to promote protective protein aggregation. 
Sti1 serves to reorganize speckled foci containing amyloid-like forms of Rnq1 
and Htt103Q into the StiF (Figure 2.10).  The StiF appears to be distinct from other 
misfolded protein deposition sites because it contains amyloid-like protein species, is 
perinuclear, and does not co-localize with an aggresome marker.  The StiF is one of five 
cytosolic protein handling centers, most of which have been characterized in both yeast 
and humans to function in protein homeostasis [30, 31, 33, 38].  The aggresome and the 
IPOD are responsible for storage of detergent insoluble and amyloid-like protein species 
[30, 38], whereas the peripheral compartment and JUNQ handle detergent soluble protein 
aggregates [30, 32].  The detection of substrate accumulation in these sites often requires 
gross protein overexpression and/or inhibition of the proteasome.  Importantly, amyloid-
like proteins are present in the StiF under conditions of modest protein expression and 
normal flux through the proteasome.  Thus, amyloid-like proteins appear to transit 
through the StiF under normal growth conditions. 
Why is accumulation of Htt103Q or [RNQ+] prions in the StiF versus other PQC 
centers cytoprotective?  Onset of [RNQ+] prion or Htt103Q toxicity is detected within 4 
hours of expression [8, 39], and at this time they appear in the cytosol as speckled 
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punctae and diffuse assemblies.  Elevation of Sti1 accelerates the sequestration of 
amyloid-like proteins into the StiF and increases detergent insoluble oligomers of 
[RNQ+] and Htt103Q over 2 fold.  This may occur by diversion of amyloidogenic 
proteins away from the IPOD where they could be sheared by Hsp104, possibly 
generating toxic oligomers [37, 58].  Shunting amyloid-like proteins away from the 
aggresome to the StiF is protective because this prevents sequestration of essential 
proteins into aggregates.  For example, [RNQ+] prions sequester Spc42 away from its 
normal function in the spindle pole body leading to cell death [59], so increasing flux of 
[RNQ+] prions to the StiF would be protective.  Accumulation of amyloid-like protein 
species in the JUNQ is cytotoxic as it inhibits normal PQC function [30, 33-35], so 
diverting these proteins to the StiF would assure normal function of the ubiquitin 
proteasome system.  The fate of proteins that enter the StiF is not entirely clear, yet these 
foci are highly stable, so they may serve as a long-term storage vault for otherwise toxic 
proteins.  
How does modulation of Sti1 alter spatial partitioning of amyloid-like aggregates?  
Sti1 promotes association of Ssa1 and Sis1 with Htt103Q while reducing the presence of 
Hsp90, thus stabilizing the Hsp70:substrate bound complex.  Sti1 interaction with the 
Hsp70 system seems to allow the co-chaperone to directly affect the substrate’s fate.  In 
support of this concept, Sti1 was found in complex with a high molecular weight 
assembly of Htt103Q, can be precipitated from this complex, and co-localizes in the StiF.  
Although Sti1 is involved in kinase maturation and folding [60], the physical association 
of Sti1 with amyloid-like protein species support a direct role for Sti1 in Hsp70 client 
handling rather than an indirect role via altering kinase signaling pathways. 
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Sti1’s cooperation with Sis1 in spatial distribution of amyloid-like proteins is 
consistent with observations that Sis1 impacts the subcellular localization of prions and 
misfolded proteins [36, 39].  During heat stress, Sis1 is proposed to interact with the 
aggregate sorting factor Btn2, targeting misfolded proteins to a juxtanuclear location 
[36].  Sis1 function is also implicated in targeting of [RNQ+] prions to the nucleus [8, 39] 
in a process that may involve Cur1 [36].  Levels of Btn2 and Cur1 during heat stress are 
thought to regulate the relative cytosolic concentrations of Sis1, thereby dictating whether 
misfolded protein accumulates with Sis1 at a juxtanuclear site or with Hsp42 at a 
peripheral cytosolic site [36].  Thus, there are protein sorting factors that interact with 
Sis1 and impact targeting of protein aggregates to different protein handling centers.  
Cur1, Btn2, and Hsp42 were deleted from strains expressing Htt103Q, but were 
dispensable for Sti1 dependent accumulation of Htt103Q in the StiF and suppression Htt 
toxicity (Figure 2.11).  Nevertheless, the existence of such spatial PQC factors suggests 
the possibility that Sti1 plays a similar role in an alternate pathway that may be specific 
for amyloid-like proteins. 
How might Sti1 reorganize the subcellular foci that contain the amyloid-like 
oligomers with which it interacts? Hsp104 functionally interacts with Ssa1, Sis1, and Sti1 
in maintenance of the yeast prion [PSI+] [21, 52], as evidenced by the observation that 
deletion of Sti1 inhibits the ability of overexpressed Hsp104 to eliminate [PSI+] [21]. 
Interestingly, both the elevation of Sti1 and inhibition of Hsp104 for a short period with 
GndHCl prevent speckled Rnq1-mRFP foci accumulation.  Yet, GndHCl promotes foci 
formation in a peripheral location and Sti1 in a perinuclear location, with Sti1 being 
dominant over GndHCl.  Inhibition of Hsp104 eliminates [RNQ+] prions from cells [41], 
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but Sti1 overexpression does not cure yeast of [RNQ+] prions (Figure 2.12A, left panel).  
However, when Hsp104 is inhibited, Sti1 elevation accelerates the rate of [RNQ+] prion 
curing caused by inhibition of Hsp104 (Figure 2.12). Thus, Sti1 is not an inhibitor or 
Hsp104.  Instead, it appears to interact with Sis1 and possibly other spatial PQC factors 
to direct amyloid-like proteins to the StiF, and this sequesters pools Rnq1 and Htt103Q 
away from the machinery that would normally break them into smaller foci.  
The co-chaperones CHIP and BAG3 target Hsp70 clients for degradation via the 
ubiquitin proteasome or autophagy, respectively [10, 13, 61].  Sti1 is now reported to 
enable Hsp70 to function in spatial PQC by targeting amyloid-like proteins to the StiF.  
Sti1 is stress inducible, and, in humans, CHIP and Sti1 differentially bind to Hsp70 and 
Hsp90 based on changes in phosphorylation [62].  Thus, under normal and stress 
conditions, subtle changes in Sti1 levels or phosphorylation status could impact targeting 
of Hsp70 clients to an alternate fate.  Sti1 is differentially expressed in various brain 
regions of both healthy humans and neurodegenerative disease patients [63, 64]. Thus, 
differences in Sti1 activity in different tissues or cell types could impact the efficiency of 
mammalian spatial PQC, influencing the onset of protein conformational disorders.  In 
the future, it will be interesting to determine if differences in the cellular set-point of 
spatial quality control factors in healthy and diseased tissues correlate with neuronal 
subpopulations where neurodegenerative diseases originate.   
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2.5 Methods 
Strains and plasmids 
 Yeast strains and plasmids are listed in Tables S1 and S2.  All strains harbored 
Rnq1 in its [RNQ+] prion form unless otherwise indicated.  The generation of isogenic 
[rnq-] strains was accomplished via sequential passage of cells on plates containing 3mM 
guanidinium-HCl.  Strains were transformed with plasmids and cultured in synthetic 
media as described previously [8].  Constructs containing a copper inducible promoter 
(CUP1) were induced at a low constitutive level from basal levels of copper in media 
unless specified that media was supplemented with additional CuSO4.  This is the case 
for all Rnq1-mRFP microscopy unless otherwise indicated.  For Sti1 overexpression 
experiments, Sti1 was always expressed from its endogenous promoter on a high copy 
plasmid.   
Expression of Htt103Q 
 Htt25Q and Htt103Q integration strains were generated using the pRS305 plasmid 
backbone.  This vector carried a construct containing an amino terminal FLAG tag, the 
first 17 amino acids of Htt, a 25 or 103 polyQ stretch, and a carboxy terminal GFP tag.  
The Htt constructs were integrated under control of a galactose inducible promoter 
(GAL1).  Htt cultures were grown in synthetic media containing 2% glucose until 
cultures reached a density of 4 OD600 or greater.  They were then diluted back in 2% 
raffinose, allowed to recover to mid-log phase growth, and finally induced for indicated 
times with 2% galactose.  Except during time courses, Htt25Q and Htt103Q were induced 
for 4 hours.  The only exception to these expression conditions was when we utilized the 
Htt103Q-Pro construct.  This construct lacked the N terminal FLAG tag and contained a 
 44
Proline rich region following the polyQ stretch.  Expression of Htt103Q-Pro was induced 
with 2% galactose for 24 h from a low copy plasmid and galactose inducible promoter. 
Toxicity assays 
Yeast samples were normalized to the same OD600, then 5 fold serial diluted in a 
sterile 96-well plate.  Each dilution was plated in 10uL spots on appropriate synthetic 
dropout media.  Most images of yeast grown on glucose were scanned at 48h and 
galactose at 72h.  Lysates for Western blots from toxicity assays were prepared using 
cultures picked from control growth plates after they were scanned.  Rnq1 toxicity was 
assessed on plates containing 2% glucose with 500uM CuSO4 and Htt toxicity plates 
contained 2% galactose. 
SDS-PAGE and Western Blotting 
Lysates were prepared from pellets of yeast by either mechanical disruption via 
glass bead breaking (for SDD-AGE and co-IP) as described previously [8, 39] or an 
alkali lysis method as described previously [34] (for samples which were directly run on 
SDS-PAGE gels).  When using mechanical disruption, the lysis buffer used was 0.1% 
Triton X-100, 75mM Tris pH7.4, 150mM NaCl, 1mM EDTA, 1mM PMSF, and Sigma 
protease inhibitor cocktail.  Standard separation techniques were used to analyze lysates 
via SDS-PAGE.  Protein was transferred to nitrocellulose for 75-90 min at 110V, and 
probed using the indicated antibodies.  Antibodies used in this study are listed in Table 
S3. 
Fluorescence microscopy 
Fluorescence microscopy was carried out as described previously [39].  Briefly, 
cultures were fixed with 4% formaldehyde and 0.1M KPO4 pH 7.4, and stored in 0.1M 
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KPO4 pH 7.4 with 1.2M sorbitol.  When dapi stained, cells were permeabilized with 
0.1% Triton in PBS, washed twice with PBS, incubated with 0.5ug/mL dapi for 10min, 
washed twice again with PBS, and resuspended in the sorbitol solution.  An Olympus 
IX81 motorized inverted fluorescence microscope paired with Metamorph software was 
used to collect images.  Micrographs were merged and processed using ImageJ.   
Immunofluorescence and thioflavin-T staining 
 Cells were collected and fixed as described above.  Following fixation, 
spheroplasts were generated using 5 mg/mL zymolyase as described for size exclusion 
chromatography below.  For thioflavin-T staining, spheroplasts were treated with 0.1% 
Triton in PBS for 10 min, then washed with sorbitol solution.  Following this 
permeabilization, cells were incubated with 0.001% thioflavin-T for 10 min, washed, and 
resuspended in sorbitol solution.  For immunofluorescence, spheroplasts were applied to 
teflon coated glass slides (Electron Microscopy Sciences) with poly-L-lysine coated 
wells.  Then wellsh were then blocked using buffer containing 0.1M KPO4 pH 7.5, 0.5% 
BSA, 0.02% Tween-20.  Primary and secondary antibodies were applied with washes 
after each.  Antibody incubation and washes all were carried out with the same blocking 
buffer.  
SDD-AGE 
Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) was carried 
out as described previously [8].  Briefly, samples were prepared via bead breaking as 
described above and normalized by a protein determination assay (DC protein assay kit; 
Bio-Rad).  Equivalent amounts of total protein were loaded on a 1.4% agarose gel 
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containing 0.1% SDS, run at 90-100V for approximately 2h, then transferred to PVDF at 
12V for 15h. 
Size exclusion chromatography 
Non-denaturing extracts from the Htt103Q strain were prepared via 
spheroplasting as follows.  Approximately 150 ODs of mid-log phase cells were 
resuspended in 2mL Z buffer containing 50mM TrisCl pH 7.5, 10 mM MgCl2, 1M 
sorbitol and 30mM DTT, then incubated at room temperature for 15min. Sample was 
then centrifuged and resuspended in 1mL Z buffer with 5mg zymolyase added (30mM 
DTT), and incubated at 30°C in shaker at 50 rpm for 45min.  Following zymolyase 
treatment, spheroplasts were centrifuged and carefully washed twice with 1mL cold Z 
buffer (1mM DTT), then thoroughly resuspend with 800uL of lysis buffer (listed above, 
without Triton) using a cold glass disposable pipet.  Samples were pre-cleared to remove 
cell debris and normalized so that the same amount of protein was loaded to the column 
each time.  A 500uL loop was loaded into a Sephacryl S200 column, and 500uL fractions 
were collected.  Western blots show every third fraction starting slightly before the void 
volume as determined by Thyroglobulin. 
Co-immunoprecipitation 
The Htt103Q strain carried either an empty vector or the YepLac-Sti1 construct, 
and were induced and lysed via bead breaking as described above.  For experiments 
where ATP was present the lysis buffer contained 75mM Tris pH7.4, 150mM NaCl, 
0.1% Triton, 10mM MgCl, and 4mM ATP.  Lysates were incubated with anti-FLAG M2 
affinity gel (Sigma).  Htt103Q which was captured was then eluted by addition of 
0.2mg/mL FLAG peptide (Sigma) and incubation at 37°C for 20min.  Following 
 47
incubation, samples were spun at 4000rpm for 5min, and supernatant was harvested, 
combined with sample buffer, and loaded on an SDS-PAGE gel along with an input 
sample.  In the case of co-IP from column fractions, two 500uL fractions were combined, 
a small amount reserved for an input sample, and the remaining sample was used for the 
IP. 
Luciferase refolding assay 
Refolding of denatured luciferase by Ssa1 and Sis1 was performed as described 
previously [65]. Briefly, firefly luciferase (13.3 mg/ml; Promega) was diluted 42-fold 
into 25 mM HEPES, pH 7.4, 50 M KCl, 5 mM MgCl2, 6 M GndHCl, 5 mM DTT and 
denatured by incubation at 25°C for 1 h. Aliquots (1 μl) were removed and added to 124 
μl of refolding buffer that was composed of 25 mM HEPES, pH 7.4, 50 mM KCl, 5 mM 
MgCl2, 1 mM ATP and contained the indicated concentration of Ssa1, Sis1, Sti1, and/or 
CHIP.  Reaction mixtures were incubated at 30°C, and 1-μl aliquots were removed and 
mixed with 60 μl of luciferase assay buffer (Promega) at the indicated timepoints and 
luminescence was collected for 10 sec with a TD20/20 luminometer (Turner Designs). 
Analysis of Rnq1 to determine Hsp104 shearing activity 
The W303yeast strain harbored either an empty vector (control) or Sti1 construct 
expressed from its endogenous promoter and p315-Cup1-Rnq1-GFP.  Cultures were 
maintained at log phase in synthetic media containing glucose.  Following addition of 
3mM guanidinium-HCl, cultures were monitored at OD600 for doubling time.  At the 
indicated generations, a portion of the culture was pelleted and frozen.  After all time 
points were collected, pellets were thawed on ice, lysed via bead breaking, and 
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normalized.  An aliquot was separated to use as the total fraction, then the remaining 
lysate was subjected to 100,000xg spin in an ultracentrifuge at 4°C.  An aliquot of the 
supernatant was collected, then the pellet resuspended in the beginning volume with the 
same lysis buffer.  A 20uL portion of each sample (total, supernatant, and pellet) was run 
on a 9% SDS-PAGE gel and transferred to nitrocellulose, then probed using anti-GFP 
antibody to monitor Rnq1 solubility.  A control culture was grown for the same amount 
of time without GndHCl and analyzed in the same way.	
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2.7 Tables and Figures 
 
 
Figure 2.1 Sti1 suppresses Htt103Q toxicity and reorganizes Htt103Q-GFP foci  
(A) Impact of Sti1 upon Htt103Q growth defect as monitored by cell growth assay plated 
in fivefold dilutions.  Htt103Q and Htt103Q-NoTox are two integration strains with 
similar Htt expression that differ in severity of the growth defect. (B) Impact of Sti1 on 
organization of Htt103Q-GFP foci. (C) Expression levels of Htt as detected by Western 
blot analysis of lysates taken from cultures grown from strains in A.  Graph depicts 
quantitation of Sti1 overexpression compared to endogenous Sti1 (n=6). (D) Expression 
level and localization of Htt103Q-GFP as in (B and C).  Here Htt103Q was expressed 
from a CUP1 promoter induced with 500uM CuSO4 for 4 h.  (E) Influence of Sti1 upon 
organization of mCitrine-Luciferase during heat shock.  Cells were imaged live during 
growth at 30°C and then again after a shift to 42°C for 20 min. (F) Co-localization of 
Htt103Q-GFP and Sti1-mRFP.  White arrows indicate co-localization.  Nuclei were 
visualized using DAPI staining.  Lysates for Western blot analysis came from cells grown 
under the same conditions used for fluorescence microscopy. 
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Figure 2.2 Sti1 specifically alters Htt103Q-GFP spatial and temporal foci formation  
(A) Sgt2 does not suppress the Htt103Q growth defect as monitored by cell growth assay 
plated in fivefold dilutions.  The toxicity assay was plated on synthetic media containing 
500uM CuSO4 to induce Sgt2 expression. (B) Impact of Sti1 upon Htt103Q-GFP foci 
formation over time.  Live images were captured at the indicated times after galactose 
induction of Htt103Q-GFP. (C) Stability of Htt103Q-GFP foci during Sti1 
overexpression as monitored by cycloheximide decay.  After 4 h of Htt103Q-GFP 
induction, cells were treated with cycloheximide, then fixed and imaged at the indicated 
times. Nuclei were visualized using DAPI staining. (D and E) Influence of (D) CHIP or 
(E) Sti1 upon Ssa1 and Sis1 chaperone activity as measured by in vitro luciferase activity 
assay.  Chaperones were added at the indicated concentrations to GndHCl treated 
luciferase and luminescence was measured as a readout for chaperone mediated 
refolding. 
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Figure 2.3 Sti1 co-fractionates with high molecular weight forms of Htt103Q  
(A) Migration of indicated forms of Htt with Sti1 on Sephacryl S200 gel filtration column 
at endogenous (control) or overexpressed Sti1 levels as detected by Western blot. (B) 
Detection of Sti1 in immune precipitates with FLAG-Htt103Q-GFP.  
Immunoprecipitation was performed with anti-FLAG conjugated beads from aliquots of 
fraction 12 containing both Htt103Q and Sti1 or from fraction 28 containing only Sti1 as 
a background control.  The IP was carried out using the column sample with elevated 
levels of Sti1 and precipitates were analyzed by Western blot. (C) Quantitation of 
Htt103Q in column fractions.  Non-denaturing lysates were prepared as described in the 
methods, and equivalent amounts of total protein per sample were applied to the S200 
column. 
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Figure 2.4 Sti1 suppresses Rnq1 toxicity and reorganizes Rnq1-mRFP foci  
(A and B) Impact of Sti1 upon the growth defect caused by Rnq1-mRFP overexpression 
as monitored by cell growth assay plated in fivefold dilutions.  Toxicity assay was plated 
on synthetic media containing 2% glucose and 500uM CuSO4. (C) Impact of Sti1 upon 
organization of Rnq1-mRFP foci.  Expression levels of Rnq1-mRFP were detected by 
Western blot analysis under conditions identical to those used for fluorescence 
microscopy and described in the methods section. 
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Figure 2.5 Sti1 modulates assembly of amyloidogenic substrates  
(A) Quantitation of Sti1 impact upon SDS-resistant Htt103Q-GFP or Rnq1-mRFP 
material as measured by SDD-AGE.  (*p<0.05, **p<0.005, n=3 or more) (B) Inability of 
Sti1 to reorganize Htt103Q-GFP or Rnq1-mRFP to foci in a [rnq-] background.  (C) 
Staining of Rnq1-mRFP foci with the amyloid indicator dye Thioflavin-T as well as 
DAPI to indicate nuclei.  (D) Co-localization of Htt103-GFP and Rnq1-mRFP during 
Sti1 overexpression.  White arrows indicate co-localization.  Insets represent the same 
punctae indicated with white arrows in the main panel. 
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Figure 2.6 Sti1 is not required for Rnq1-NLS relocalization of Htt103Q to the 
nucleus  
(A) Lack of Sti1 dependence for Rnq1-mRFP-NLS to target Htt103Q-GFP to the 
nucleus.  Rnq1 was tagged with the SV40 NLS signal and expressed at low levels from 
the CUP1 promoter as in other Rnq1-mRFP localization studies.  Samples expressed 
either Rnq1-mRFP-NLS, Htt103Q-GFP, or both as indicated. (B) Impact of Sti1 deletion 
upon foci formation of Htt103Q-GFP containing a proline rich region.  Nuclei were 
visualized using DAPI staining.   
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Figure 2.7 The StiF is a juxtanuclear compartment for amyloid-like proteins  
(A and B) Localization of endogenous (A) Hsp104 or (B) Hsp42 as monitored by 
immunofluorescence using Htt103Q as a StiF marker.  (C and D) Impact of Hsp104 
inhibition upon Rnq1-mRFP localization at the StiF.  Fluorescence microscopy was 
carried out in strains with (C) Spc42 or (D) Hsp42 tagged at the endogenous locus with 
GFP.  Rnq1-mRFP was induced with 50uM CuSO4 and Hsp104 was inhibited with 3mM 
GndHCl for 2 h before cells were fixed.  Nuclei were visualized using DAPI staining. 
Dotted lines indicate the outline of the cell. 
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Figure 2.8 Sti1 reorganizes complexes that contain Htt103Q and Hsp70  
(A) Diagram of Sti1’s domain structure. (B) Impact of mutating different Sti1 TPR 
domains upon ability to suppress Htt103Q growth defect as monitored by cell growth 
assay plated in fivefold dilutions. (C) Sti1 and Htt103Q expression as monitored by 
Western blot analysis of strains shown in (B). (D) Impact of select Sti1 point mutations 
upon Sti1’s ability to reorganize Htt103Q. (E) Impact of elevated Sti1 upon the 
multichaperone:substrate complex as monitored by co-immunoprecipitation of Htt103Q 
and Western blot of indicated chaperones.  CoIPs were carried out in the absence or 
presence of ATP as indicated above each group of panels.  (F) Quantitation of chaperones 
which co-immunoprecipitated with Htt103Q in E.  (*p<0.05, **p<0.005, n=3 or more) 
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Figure 2.9 Sti1 and Sis1 cooperate to regulate Rnq1 and Htt103Q toxicity  
(A and B) Inability of Sis1 to suppress growth defect of (A) Rnq1-mRFP (p423-CUP1 
plasmid) or (B) Htt103Q (toxic integration strain) in a Sti1 deletion strain as monitored 
by cell growth assay plated in fivefold dilutions.  Expression levels of Sti1, Sis1, and 
Htt103Q or Rnq1 were measured by Western blot analysis. (C) Impact of elevated Sti1 
upon subcellular localization of Sis1 during Rnq1-mRFP expression.  Experiments were 
carried out in a strain where Sis1 was tagged at the endogenous locus with GFP. 
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Figure 2.10 Model for StiF formation  
Sti1 acts in cooperation with Ssa1 and Sis1 to redirect amyloid-like material from the 
IPOD prion shearing center to the StiF which is present under normal growth conditions.  
The StiF contains Hsp104, but not Hsp42, and is not localized at the spindle pole body 
(SPB). 
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Figure 2.11 Other cellular sorting factors are not necessary for Sti1’s mechanism of 
action  
(A) Impact of deletion of indicated proteins upon Sti1’s ability to suppress Htt103Q 
growth defect as monitored by cell growth assay plated in fivefold dilutions. (B) Impact 
of deletion of indicated proteins upon Sti1’s ability to reorganize Htt103Q-GFP. Toxicity 
and fluorescence microscopy assays were carried out as in Figure 2.1. 
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Figure 2.12 Sti1 attenuates Hsp104 shearing activity in the presence of GndHCl   
(A) Curing rate of [RNQ+] is increased in the presence of GndHCl when Sti1 is 
overexpressed as indicated by triton solubility assay followed by Western blot.  Since 
[RNQ+] is triton insoluble, we measured the Rnq1 triton solubility from lysates with 
endogenous and overexpressed Sti1 at the indicated generations post GndHCl treatment.  
Increased Sti1 does not completely inactivate Hsp104 and cure the cells of [RNQ+] as 
indicated in the left panel without GndHCl treatment.  (B) Quantitation of curing rate in 
(A) as measured by ratio of soluble to insoluble Rnq1.   
 
 
 62
REFERENCES 
 
1. Carrell, R.W. and D.A. Lomas, Conformational disease. Lancet, 1997. 350(9071): 
p. 134-8. 
2. Chiti, F. and C.M. Dobson, Protein misfolding, functional amyloid, and human 
disease. Annu Rev Biochem, 2006. 75: p. 333-66. 
3. Treusch, S., D.M. Cyr, and S. Lindquist, Amyloid deposits: protection against 
toxic protein species? Cell Cycle, 2009. 8(11): p. 1668-74. 
4. Haass, C. and D.J. Selkoe, Soluble protein oligomers in neurodegeneration: 
lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol, 2007. 
8(2): p. 101-12. 
5. Bucciantini, M., et al., Prefibrillar amyloid protein aggregates share common 
features of cytotoxicity. J Biol Chem, 2004. 279(30): p. 31374-82. 
6. Cohen, E., et al., Opposing activities protect against age-onset proteotoxicity. 
Science, 2006. 313(5793): p. 1604-10. 
7. Wolfe, K.J. and D.M. Cyr, Amyloid in neurodegenerative diseases: friend or foe? 
Semin Cell Dev Biol, 2011. 22(5): p. 476-81. 
8. Douglas, P.M., et al., Chaperone-dependent amyloid assembly protects cells from 
prion toxicity. Proc Natl Acad Sci U S A, 2008. 105(20): p. 7206-11. 
9. Muchowski, P.J. and J.L. Wacker, Modulation of neurodegeneration by 
molecular chaperones. Nat Rev Neurosci, 2005. 6(1): p. 11-22. 
10. Cyr, D.M., T. Langer, and M.G. Douglas, DnaJ-like proteins: molecular 
chaperones and specific regulators of Hsp70. Trends Biochem Sci, 1994. 19(4): 
p. 176-81. 
11. Tyedmers, J., A. Mogk, and B. Bukau, Cellular strategies for controlling protein 
aggregation. Nat Rev Mol Cell Biol, 2010. 11(11): p. 777-88. 
 63
12. Cyr, D.M., J. Hohfeld, and C. Patterson, Protein quality control: U-box-
containing E3 ubiquitin ligases join the fold. Trends Biochem Sci, 2002. 27(7): p. 
368-75. 
13. Meacham, G.C., et al., The Hsc70 co-chaperone CHIP targets immature CFTR 
for proteasomal degradation. Nat Cell Biol, 2001. 3(1): p. 100-5. 
14. Langer, T., et al., Successive action of DnaK, DnaJ and GroEL along the pathway 
of chaperone-mediated protein folding. Nature, 1992. 356(6371): p. 683-9. 
15. Liberek, K., et al., Escherichia coli DnaJ and GrpE heat shock proteins jointly 
stimulate ATPase activity of DnaK. Proc Natl Acad Sci U S A, 1991. 88(7): p. 
2874-8. 
16. Cyr, D.M., X. Lu, and M.G. Douglas, Regulation of Hsp70 function by a 
eukaryotic DnaJ homolog. J Biol Chem, 1992. 267(29): p. 20927-31. 
17. Scheufler, C., et al., Structure of TPR domain-peptide complexes: critical 
elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell, 
2000. 101(2): p. 199-210. 
18. Shaner, L., et al., The yeast Hsp110 Sse1 functionally interacts with the Hsp70 
chaperones Ssa and Ssb. J Biol Chem, 2005. 280(50): p. 41262-9. 
19. Steel, G.J., et al., Coordinated activation of Hsp70 chaperones. Science, 2004. 
303(5654): p. 98-101. 
20. Hernandez, M.P., W.P. Sullivan, and D.O. Toft, The assembly and intermolecular 
properties of the hsp70-Hop-hsp90 molecular chaperone complex. J Biol Chem, 
2002. 277(41): p. 38294-304. 
21. Reidy, M. and D.C. Masison, Sti1 regulation of Hsp70 and Hsp90 is critical for 
curing of Saccharomyces cerevisiae [PSI+] prions by Hsp104. Mol Cell Biol, 
2010. 30(14): p. 3542-52. 
22. Roffe, M., et al., Prion protein interaction with stress-inducible protein 1 
enhances neuronal protein synthesis via mTOR. Proc Natl Acad Sci U S A, 2010. 
107(29): p. 13147-52. 
 64
23. Jones, G., et al., Propagation of Saccharomyces cerevisiae [PSI+] prion is 
impaired by factors that regulate Hsp70 substrate binding. Mol Cell Biol, 2004. 
24(9): p. 3928-37. 
24. Chen, S., et al., Differential interactions of p23 and the TPR-containing proteins 
Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress Chaperones, 
1998. 3(2): p. 118-29. 
25. Dai, Q., et al., CHIP activates HSF1 and confers protection against apoptosis and 
cellular stress. EMBO J, 2003. 22(20): p. 5446-58. 
26. Qian, S.B., et al., CHIP-mediated stress recovery by sequential ubiquitination of 
substrates and Hsp70. Nature, 2006. 440(7083): p. 551-5. 
27. Jiang, J., et al., CHIP is a U-box-dependent E3 ubiquitin ligase: identification of 
Hsc70 as a target for ubiquitylation. J Biol Chem, 2001. 276(46): p. 42938-44. 
28. Olzscha, H., et al., Amyloid-like aggregates sequester numerous metastable 
proteins with essential cellular functions. Cell, 2011. 144(1): p. 67-78. 
29. Last, N.B., E. Rhoades, and A.D. Miranker, Islet amyloid polypeptide 
demonstrates a persistent capacity to disrupt membrane integrity. Proc Natl Acad 
Sci U S A, 2011. 108(23): p. 9460-5. 
30. Kaganovich, D., R. Kopito, and J. Frydman, Misfolded proteins partition between 
two distinct quality control compartments. Nature, 2008. 454(7208): p. 1088-95. 
31. Johnston, J.A., C.L. Ward, and R.R. Kopito, Aggresomes: a cellular response to 
misfolded proteins. J Cell Biol, 1998. 143(7): p. 1883-98. 
32. Specht, S., et al., Hsp42 is required for sequestration of protein aggregates into 
deposition sites in Saccharomyces cerevisiae. J Cell Biol, 2011. 195(4): p. 617-
29. 
33. Weisberg, S.J., et al., Compartmentalization of superoxide dismutase 1 
(SOD1G93A) aggregates determines their toxicity. Proc Natl Acad Sci U S A, 
2012. 109(39): p. 15811-6. 
 65
34. Summers, D.W., et al., The Type II Hsp40 Sis1 cooperates with Hsp70 and the E3 
ligase Ubr1 to promote degradation of terminally misfolded cytosolic protein. 
PLoS One, 2013. 8(1): p. e52099. 
35. Shiber, A., et al., Ubiquitin conjugation triggers misfolded protein sequestration 
into quality-control foci when Hsp70 chaperone levels are limiting. Mol Biol 
Cell, 2013. 
36. Malinovska, L., et al., Molecular chaperones and stress-inducible protein sorting 
factors coordinate the spatio-temporal distribution of protein aggregates. Mol 
Biol Cell, 2012. 
37. Tyedmers, J., et al., Prion induction involves an ancient system for the 
sequestration of aggregated proteins and heritable changes in prion 
fragmentation. Proc Natl Acad Sci U S A, 2010. 107(19): p. 8633-8. 
38. Wang, Y., et al., Abnormal proteins can form aggresome in yeast: aggresome-
targeting signals and components of the machinery. FASEB J, 2009. 23(2): p. 
451-63. 
39. Douglas, P.M., et al., Reciprocal Efficiency of RNQ1 and Polyglutamine 
Detoxification in the Cytosol and Nucleus. Mol Biol Cell, 2009. 
40. Summers, D.W., et al., The type I Hsp40 Ydj1 utilizes a farnesyl moiety and zinc 
finger-like region to suppress prion toxicity. J Biol Chem, 2009. 284(6): p. 3628-
39. 
41. Sondheimer, N. and S. Lindquist, Rnq1: an epigenetic modifier of protein 
function in yeast. Mol Cell, 2000. 5(1): p. 163-72. 
42. Derkatch, I.L., et al., Prions affect the appearance of other prions: the story of 
[PIN(+)]. Cell, 2001. 106(2): p. 171-82. 
43. Meriin, A.B., et al., Huntington toxicity in yeast model depends on polyglutamine 
aggregation mediated by a prion-like protein Rnq1. J Cell Biol, 2002. 157(6): p. 
997-1004. 
44. Duennwald, M.L., et al., Flanking sequences profoundly alter polyglutamine 
toxicity in yeast. Proc Natl Acad Sci U S A, 2006. 103(29): p. 11045-50. 
 66
45. Dehay, B. and A. Bertolotti, Critical role of the proline-rich region in Huntingtin 
for aggregation and cytotoxicity in yeast. J Biol Chem, 2006. 281(47): p. 35608-
15. 
46. Nicolet, C.M. and E.A. Craig, Isolation and characterization of STI1, a stress-
inducible gene from Saccharomyces cerevisiae. Mol Cell Biol, 1989. 9(9): p. 
3638-46. 
47. Floer, M., G.O. Bryant, and M. Ptashne, HSP90/70 chaperones are required for 
rapid nucleosome removal upon induction of the GAL genes of yeast. Proc Natl 
Acad Sci U S A, 2008. 105(8): p. 2975-80. 
48. Prodromou, C., et al., Regulation of Hsp90 ATPase activity by tetratricopeptide 
repeat (TPR)-domain co-chaperones. EMBO J, 1999. 18(3): p. 754-62. 
49. Sondheimer, N., et al., The role of Sis1 in the maintenance of the [RNQ+] prion. 
EMBO J, 2001. 20(10): p. 2435-42. 
50. Aron, R., et al., J-protein co-chaperone Sis1 required for generation of [RNQ+] 
seeds necessary for prion propagation. EMBO J, 2007. 26(16): p. 3794-803. 
51. Tipton, K.A., K.J. Verges, and J.S. Weissman, In vivo monitoring of the prion 
replication cycle reveals a critical role for Sis1 in delivering substrates to 
Hsp104. Mol Cell, 2008. 32(4): p. 584-91. 
52. Kryndushkin, D.S., et al., Increased expression of Hsp40 chaperones, 
transcriptional factors, and ribosomal protein Rpp0 can cure yeast prions. J Biol 
Chem, 2002. 277(26): p. 23702-8. 
53. LeVine, H., 3rd, Thioflavine T interaction with synthetic Alzheimer's disease beta-
amyloid peptides: detection of amyloid aggregation in solution. Protein Sci, 1993. 
2(3): p. 404-10. 
54. Jung, G. and D.C. Masison, Guanidine hydrochloride inhibits Hsp104 activity in 
vivo: a possible explanation for its effect in curing yeast prions. Curr Microbiol, 
2001. 43(1): p. 7-10. 
 67
55. Ferreira, P.C., et al., The elimination of the yeast [PSI+] prion by guanidine 
hydrochloride is the result of Hsp104 inactivation. Mol Microbiol, 2001. 40(6): p. 
1357-69. 
56. Flom, G., et al., Definition of the minimal fragments of Sti1 required for 
dimerization, interaction with Hsp70 and Hsp90 and in vivo functions. Biochem J, 
2007. 404(1): p. 159-67. 
57. Song, Y. and D.C. Masison, Independent regulation of Hsp70 and Hsp90 
chaperones by Hsp70/Hsp90-organizing protein Sti1 (Hop1). J Biol Chem, 2005. 
280(40): p. 34178-85. 
58. Chernoff, Y.O., et al., Role of the chaperone protein Hsp104 in propagation of 
the yeast prion-like factor [psi+]. Science, 1995. 268(5212): p. 880-4. 
59. Treusch, S. and S. Lindquist, An intrinsically disordered yeast prion arrests the 
cell cycle by sequestering a spindle pole body component. J Cell Biol, 2012. 
197(3): p. 369-79. 
60. Lee, P., et al., Sti1 and Cdc37 can stabilize Hsp90 in chaperone complexes with a 
protein kinase. Mol Biol Cell, 2004. 15(4): p. 1785-92. 
61. Gamerdinger, M., et al., BAG3 mediates chaperone-based aggresome-targeting 
and selective autophagy of misfolded proteins. EMBO Rep, 2011. 12(2): p. 149-
56. 
62. Muller, P., et al., C-terminal phosphorylation of Hsp70 and Hsp90 regulates 
alternate binding to co-chaperones CHIP and HOP to determine cellular protein 
folding/degradation balances. Oncogene, 2012. 
63. Martins-de-Souza, D., et al., Proteomic analysis identifies dysfunction in cellular 
transport, energy, and protein metabolism in different brain regions of atypical 
frontotemporal lobar degeneration. J Proteome Res, 2012. 11(4): p. 2533-43. 
64. Hawrylycz, M.J., et al., An anatomically comprehensive atlas of the adult human 
brain transcriptome. Nature, 2012. 489(7416): p. 391-9. 
65. Lee, S., et al., Identification of essential residues in the type II Hsp40 Sis1 that 
function in polypeptide binding. J Biol Chem, 2002. 277(24): p. 21675-82.
 
 
 
 
 
CHAPTER 3 
Identification of polyglutamine rich proteins that alter huntingtin toxicity and 
aggregation 
 
3.1 Overview 
Protein conformational maladies such as Huntington Disease (HD) are characterized by 
accumulation of intracellular and extracellular protein inclusions. In HD, disease onset 
and cell death occurs after protease cleavage of the polyglutamine expanded huntingtin 
(Htt) protein, followed by translocation into the nucleus where an N-terminal fragment 
accumulates in inclusions. Interestingly, there is an inverse correlation between Htt 
toxicity and aggregation, suggesting that protein aggregation is a cellular coping 
mechanism for an otherwise toxic species.  To more clearly understand cellular 
mechanisms for suppression of proteotoxicity, we carried out a high copy screen for 
suppressors of growth defects caused by nuclear polyglutamine expanded huntingtin 
(Htt103Q). Nuclear Htt103Q is highly toxic and less aggregation prone than its cytosolic 
form, so we screened for proteins that suppress toxicity while promoting aggregation of 
nuclear Htt103Q. We identified Nab3, Pop2, and Cbk1, which themselves contain polyQ-
rich regions, as suppressors of Htt toxicity.  Nab3 is an essential nuclear protein that 
functions in RNA processing, which appears to be inactivated by Htt103Q.  Function of 
Pop2 and Cbk1 does not appear to be impacted by nuclear Htt103Q, as their respective 
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polyQ-rich domains are sufficient to suppress Htt103Q toxicity.  Elevation of Pop2 and 
Cbk1 increases accumulation of detergent insoluble Htt103Q, and drives Htt103Q into 
perinuclear protein quality control centers.  Pop2 and Cbk1 action is dependent upon the 
Hsp70 co-chaperone Sti1 which functions in packaging of amyloid-like proteins into 
benign aggregates.  Data presented suggest that Htt103Q interacts with its polyQ domain 
containing neighbors with differing outcomes.  Some interactions are harmful due to 
sequestration away from essential functions while other interactions are beneficial 
because they result in funneling of toxic Htt103Q species to the Hsp70-Sti1 pathway and 
assembly into benign aggregates.  
3.2 Introduction 
A variety of human disorders, termed conformational disorders (CD), result from 
misfolding and aggregation of different underlying proteins [1].  Intracellular and 
extracellular inclusions found in tissue of affected individuals contain amyloid-like 
proteins that are enriched in beta-sheet structure, are detergent insoluble, and bind 
amyloid indicator dyes [1-4].  Amyloid assembly is a regulated process which occurs 
through a nucleated polymerization reaction [5].  When soluble protein interacts with 
templated species, it gets incorporated into the growing amyloid fibril demonstrating that 
protein-protein interactions mediate polymerization [6-8].  Whether the amyloid-like 
aggregates themselves are causative or a protective cellular defense mechanism against 
an unknown toxic species is a topic of debate [3].  The harmful species in some CD may 
be small oligomeric intermediates of the templated aggregation pathway while 
accumulation of larger benign assemblies may either be a by-product of such a pathway 
or a productive defense mechanism [9-16].  Therefore, protection against proteotoxicity 
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in CD may involve either preventing entry of native proteins into the amyloid-like 
assembly pathway or, once entry has already occurred, driving formation of a benign 
aggregate species.  In both cases, the cell would be diverting proteins away from a toxic 
aggregation pathway intermediate. 
Huntington Disease (HD) is one of several maladies associated with expansion of 
a polyglutamine (polyQ) tract within a disease associated gene (HTT).  Protease cleavage 
of the full length polyQ expanded Htt protein is necessary for HD onset and cell death 
[17,18].  N-terminal fragments of Htt are translocated into the nucleus where they 
accumulate in inclusions [19].  Both cytoplasmic and intranuclear Htt inclusions are 
associated with HD [19-21], but toxicity and behavioral phenotypes are more severe 
when Htt is targeted to the nucleus [22-24].  While a clear mechanistic understanding of 
nuclear versus cytosolic polyQ toxicity remains to be discovered, several factors have 
been implicated in this process.  The relative concentration of proteostatic factors in the 
cytosol and nucleus are different creating a specific environment in each subcellular 
location.  The nuclear environment may not be as well-equipped as the cytosol to handle 
toxic species of polyQ proteins.  Disease related polyQ proteins can titrate essential 
nuclear proteins such as transcription factors away from normal function leading to 
transcriptional dysregulation and to cell death [25-28].  PolyQ proteins can also interfere 
with function of protein quality control components such as the ubiquitin proteasome [29-
31].  Molecular chaperones help prevent polyQ toxicity by refolding, targeting protein for 
degradation, or promoting aggregation [3,32-34].  These examples provide evidence that 
protein-protein interactions have both positive and negative influences on the cell’s 
ability to buffer expression of potentially toxic proteins [35-38].   
 71
Many of the basic principles of chaperone modulation of proteotoxicy and 
aggregation come from ectopic expression of disease related proteins in yeast.  Yeast 
expressing a construct (Htt103Q) containing the first 17 amino acids from  HTT exon 1 
and a polyQ tract of 103 residues and lacking the proline domain recapitulates polyQ 
length dependent aggregation and toxicity [6,24,39].  As in mammalian systems, addition 
of a nuclear localization signal (NLS) caused this protein to be even more toxic [24].  In 
the yeast model, enhanced toxicity of Htt103Q-NLS was associated with decreased 
packaging into SDS-resistant aggregates [24].  Htt103Q aggregation and toxicity is 
dependent on the conformation of the glutamine/asparagine-rich yeast prion protein Rnq1 
[6,40].  Interaction of Htt103Q and [RNQ+] prion causes templating of Htt103Q into an 
amyloid-like conformation [6,40].  Sti1, an Hsp70 co-chaperone, seems to be one factor 
that contributes to a cells capacity to buffer proteotoxicity of polyQ proteins in the 
cytosol.  We recently characterized a role for Sti1 in promoting protective aggregation of 
Htt103Q.  Increased SDS-resistant aggregation correlated with accumulation of Htt103Q 
at a perinuclear compartment, demonstrating that Sti1 functions in a pathway for 
packaging Htt103Q into a protective quality control compartment (Chapter 2).  Targeting 
Htt103Q to the nucleus may remove the substrate from an environment where a toxic 
species would have been sequestered into a benign SDS-resistant inclusion.   
In order to better understand the pathway for protective aggregation, we carried 
out a high copy toxicity suppressor screen utilizing Htt103Q-NLS as the substrate.  The 
nuclear Htt103Q, which is more toxic yet more detergent soluble, allowed us to identify 
suppressors of proteotoxicity which also impacted Htt aggregation.  We further 
characterized screen hits in the context of Htt103Q to better understand these aggregation 
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phenotypes.  Although numerous other studies have screened for factors impacting polyQ 
toxicity or aggregation [6,35-38,41-46], our approach of utilizing the nuclear Htt103Q 
allowed us to identify novel components promoting protective aggregation.  Strikingly, 
over half of the genomic fragments that suppressed toxicity included ORFs encoding 
polyQ containing proteins.  While characterizing the Htt103Q aggregation phenotype of 
several of these polyQ genes, we discovered that Nab3 had little effect upon aggregation 
and required a functional RNA binding domain to suppress Htt103Q-NLS toxicity.  Pop2 
and Cbk1 promoted protective aggregation through interaction of their polyQ-rich 
regions with Htt103Q.  Modification of Htt103Q aggregation was dependent upon Sti1, 
another recently described screen hit (Chapter 2).  These data demonstrate that polyQ 
proteotoxicity can be modulated by multiple mechanisms and suggest that polyQ 
interactions can drive Htt103Q towards chaperone mediated protective aggregation. 
3.3 Results 
3.3.1 Genomic fragments from high copy screen suppress Htt103Q-NLS toxicity  
In order to understand mechanisms for protective aggregation of polyQ, we 
screened a yeast high copy expression library for toxicity suppressors of a more toxic and 
more soluble Htt103Q [24].  The proteotoxic substrate utilized in the screen contains an 
N terminal FLAG tag, the first 17 amino acids encoded by HTT exon 1, a polyQ stretch 
of 103 amino acids, a C terminal GFP tag, and the SV40 nuclear localization signal 
(NLS), and it lacks the proline-rich region (Htt103Q-NLS).  A galactose inducible form 
of Htt103Q-NLS was integrated into a W303 strain which causes a growth arrest that 
can be seen when cells are plated on solid media containing galactose.  This strain was 
transformed with a yeast multicopy expression library [22], and visible colonies after 3 
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days growth on galactose were isolated.  Following plasmid rescue and sequencing of all 
23 plasmid dependent suppressors, it was evident that several hits contained overlapping 
regions of DNA suggesting that the screen reached saturation.  
The screen revealed 12 fragments of DNA that alleviated Htt103Q-NLS toxicity 
which were designated number 1 to 12 (Table 3.1 and Figure 3.1A).  Each of the hits 
recovered from the suppressor screen contained a portion of DNA approximately 5-10 Kb 
long, which included 1-7 ORFs (Table 3.1).  Several of these hits (genomic fragments 5, 
6, 10, and 12) decreased steady state protein levels of Htt103Q-NLS (Figure 3.1B).  This 
was likely the reason for suppression of Htt103Q-NLS toxicity and so these fragments 
were excluded from further verification.  Two of the hits (genomic fragments 11 and 12) 
contained ORFs encoding proteins involved in sugar metabolism so we also excluded 
these from further validation as this was likely an artifact of the promoter used to induce 
Htt103Q-NLS expression.   
Notably, we observed that 7 of the 12 genomic fragments (GF) contained ORFs 
encoding a polyQ-rich region (Table 3.1).  Additionally, several hits (GF 1-3, 6 and 7) 
increased intranuclear Htt103Q-NLS aggregation as monitored both by intensity of 
fluorescent foci and number of cells containing nuclear foci (Figure 3.1C).  An example 
of control cells expressing diffuse Htt103Q-NLS, as well as an example of intranuclear 
foci are depicted for reference (Figure 3.1C).  Since decreased SDS-resistant aggregation 
leads to enhanced Htt103Q toxicity of the nuclear localized construct [24], we reasoned 
that increased aggregation should correlate with lower toxicity as was seen in several of 
the screen hits.  Thus, we focused our attention on further verifying individual genes from 
GF 1-4, and 6-8 as these altered aggregation and/or contained a polyQ ORF.  Individual 
 74
genes from each of these full length screen hits were subcloned with the 5’ and 3’ 
untranslated regions into a high copy plasmid to replicate expression conditions during 
the screen.  No single gene in GF 6-8 recapitulated toxicity suppression indicating that 
there was likely a combinatorial effect of several genes.  We identified 4 genes, Sti1, 
Pop2, Cbk1, and Nab3, encoding proteins which can independently act to suppress 
Htt103Q-NLS toxicity when they are overexpressed.  Sti1 is an Hsp70 co-chaperone that 
functions to suppress Htt103Q toxicity by promoting accumulation of amyloid-like 
material in perinuclear foci (Chapter 2).  Herein, we investigated the mechanism by 
which elevation of the levels of Pop2, Cbk1, and Nab3 suppress toxicity of Htt103Q. 
3.3.2 PolyQ-rich proteins suppress Htt103Q-NLS and Htt103Q toxicity 
Pop2 and Cbk1 contain polyQ-rich regions N-terminal to the functional domain of 
the proteins while the Nab3 contains a polyQ-rich region located C-terminally to the 
functional region (Figure 3.2A).  Each of these “polyQ-rich” regions contains several 
stretches of Q repeats of 6 or more residues (Figure 3.3A and 3.3B).  While stretches in 
between these polyQ tracts contain some hydrophobic residues, there is little sequence 
similarity between the polyQ-rich regions of these 3 proteins besides the polyQ tracts 
themselves (Figure 3.3C).  These polyQ-rich domains are predicted to have a relatively 
high propensity for being disordered [47] suggesting they are conformationally dynamic.  
Conformational switching is a characteristic of prion proteins which can be folded 
normally or adopt a self-propagating amyloid-like conformation.  Pop2, Cbk1, and Nab3 
were all hits in a bioinformatics screen for novel prion domain containing proteins [48].  
The criteria for determining prion domains were based upon an algorithim that searched 
for sequences similar to the prion domains of the yeast prions Sup35, Ure2, and Rnq1.  
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Based upon the prion domain forming ranking system for the top 100 hits, Cbk1, Nab3, 
and Pop2 fell at positions 6, 41, and 51, respectively [48].  When expressed in yeast, the 
prion domains of Cbk1 and Pop2 formed SDS-resistant oligomers, while Nab3 did not 
[48]. Thus, Cbk1 and Pop2, but not Nab3, contain a polyQ-rich region which may have 
some intrinsic aggregation propensity and has similar properties to previously 
characterized yeast prion domains such as in the [RNQ+] prion. 
Overexpression of Pop2, Cbk1, and Nab3 each partially suppressed toxicity of 
both Htt103Q-NLS and a similar construct lacking the NLS (Htt103Q) which aggregates 
in the cytosol (Figure 3.2B).  Reduced toxicity was not due to altered levels of the Htt 
proteins (Figure 3.2B).  As each of these proteins was expressed from its endogenous 
promoter, each protein was expressed above its own normal steady state levels to a 
different extent.  Cbk1, having a lower relative abundance than the Pop2 and Nab3 [49], 
was elevated approximately 1.5 fold over endogenous protein levels.  Nab3 and Pop2 
were elevated approximately 2.4 and 3 fold over their endogenous forms respectively.  
As was seen with the full length GF for each of these suppressors, reduction in Htt103Q-
NLS toxicity correlated with changes in aggregation during Pop2 and Cbk1, but not 
Nab3, over-expression (Figure 3.2C).  Overexpression of Cbk1 and Pop2 caused 
cytosolic speckled Htt103Q-GFP to be condensed to one or two perinuclear foci which 
was even more dramatically noticeable than changes in Htt103Q-NLS aggregation.   
Since Htt103Q toxicity and aggregation in yeast depends upon the templated 
status of the prion protein Rnq1 [6,40], we next examined whether or not these 
suppressors also alleviated the growth defect associated with Rnq1 overexpression.  The 
polyQ-rich proteins specifically acted upon Htt103Q as they were unable to suppress 
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toxicity associated with Rnq1 overexpression (Figure 3.2D).  When Rnq1 is in the [rnq-] 
non-prion conformation, Htt103Q is no longer toxic.  Using Pop2 as a representative, we 
ruled out the possibility that the polyQ-rich proteins altered Rnq1 prion status because 
expression of the polyQ proteins did not alter the templated status of Rnq1 as evidenced 
by Rnq1-GFP aggregation during Pop2 overexpression (Figure 3.2E).  Likewise, the 
polyQ-rich suppressors did not co-localize with Rnq1 aggregates (Figure 3.2E).  Thus, 
Pop2, Cbk1, and Nab3 over-expression only modulates toxicity and aggregation of 
Htt103Q without any impact upon a yeast prion protein. 
As Cbk1 and Pop2 alter Htt103Q aggregation and Nab3 does not, these proteins 
appear to fall into two different classes of polyQ-rich proteins whose elevation can 
suppress Htt103Q toxicity.  Additionally, although the polyQ-rich proteins identified in 
our screen suppress polyQ expanded Htt toxicity, other polyQ-rich proteins actually 
enhance toxicity [50].  The toxicity enhancers described in that study also were hits 
ranked within the top100 in the above mentioned prion domain screen [48].  These data 
implicate polyQ-rich proteins as having a multifaceted role in proteotoxicity of a polyQ 
disease related protein.  Therefore, we sought to distinguish the different mechanisms of 
toxicity suppression in order to better understand basic principles of how the cell buffers 
toxicity of polyQ expanded proteins and is impacted by neighboring molecules. 
3.3.3 Functional Nab3 is required for suppression of Htt toxicity 
 Nab3 is an essential nuclear protein that functions in the Nrd1 complex as an 
RNA binding protein through its RNA recognition motif [51,52].  Htt103Q-NLS may 
titrate Nab3 away from its normal function, depleting the cell of an essential protein.  In 
order to determine if this is the case, we carried out a structure/function analysis to 
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determine if overexpressed Nab3 required a functional domain in order to suppress 
Htt103Q-NLS toxicity.  In these studies, we employed a strain where Nab3 expression 
halts when the cells are grown in the presence of doxycycline (Figure 3.4A).  A mutation 
within the RNA recognition motif at S399, but not at the neighboring S397, inactivates 
Nab3 function rendering the yeast inviable if this is the sole copy of Nab3 in the cell 
(Figure 3.5A) [52].  The Nab3(S397A) is expressed at a lower level than Nab3(399A) yet 
still allows for normal growth.  This observation suggests that Nab3(S399A) has not lost 
ability to complement Nab3 depletion due to low expression levels.  Expression of a 
version of Nab3 lacking the C-terminal polyQ-rich region also failed to complement the 
deletion strain (Figure 3.5A).   
Utilizing these Nab3 constructs, we examined which form of Nab3 was able to 
impact Htt103Q-NLS toxicity.  The only forms of Nab3 that were able to suppress 
Htt103Q-NLS toxicity when over-expressed were functional forms that were able to 
complement Nab3 depletion (Figure 3.5B).  Neither the Q-rich deletion nor the E399A 
forms of Nab3 alleviated the Htt103Q-NLS growth defect (Figure 3.5B).  Since a non-
functional, polyQ-rich containing Nab3 was unable to suppress toxicity, it appears that 
the polyQ-rich region of Nab3 is not sufficient to suppress toxicity.  In monitoring 
subcellular localization, we found that a monomeric RFP (mRFP) tagged form of Nab3 
and Htt103Q-NLS are both localized in the nucleus (Figure 3.5C).  At this level of 
expression, the Htt103Q-NLS protein forms small punctae in approximately 30-40%% of 
cells expressing the construct while the remaining population exhibits a diffuse nuclear 
signal as described previously [24].  When Htt103Q-NLS was co-expressed with Nab3-
mRFP, the nuclear Nab3-mRFP became enriched in the location where the Htt103Q-NLS 
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punctae formed, but the same approximate number of cells exhibited the Htt punctae 
(Figure 3.5C).  These data suggest that, although its aggregation status does not change, 
Htt103Q-NLS interacts with Nab3.  In support of this hypothesis, Nab3 was identified in 
a mass spectrometry screen which utilized SILAC labeling to quantitatively determine 
interaction partners of a Htt construct with a 96 residue polyQ tract [53].  If Htt103Q-
NLS titrates Nab3 away from its normal and essential function, then suppression of 
toxicity by overexpression would occur by replacing the lost functional protein.  This is a 
partial suppression of toxicity because Nab3 is one of numerous other proteins such as 
transcription factors likely to also be titrated away from their normal functions [28,54]. 
3.3.4 The polyQ-rich region of Cbk1 forms perinuclear foci where Htt103Q 
accumulates during toxicity suppression 
 Cbk1 and Pop2 suppress polyQ expanded Htt toxicity and impact Htt103Q 
aggregation.  To explore this mechanism, we utilized Htt103Q because these are 
cytosolic proteins and are able to alter aggregation of cytosolic Htt103Q more distinctly 
than Htt103Q-NLS.  Cbk1 is a kinase of the Ndr/Lats family and functions in the 
regulation of Ace2 and morphogenesis network [55].  However, this function of Cbk1 is 
not necessary for the protein to act as a Htt103Q toxicity suppressor because over-
expression of either a kinase dead form (Cbk1(D475A)-mRFP) [55] or the N-terminal 
portion of Cbk1 containing the polyQ-rich region and lacking the functional domain 
(Cbk1(1-326)-mRFP) could still alleviate Htt103Q toxicity (Figure 3.6A).  Conversely, 
expression of Cbk1 lacking the polyQ-rich region (Cbk1(327-756)-mRFP) was unable to 
alleviate Htt103Q toxicity even though the expression level of Cbk1(327-756)-mRFP was 
approximately equivalent to that of full length Cbk1 (Figure 3.6A).   
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As the N-terminus of Cbk1 was necessary and sufficient for toxicity suppression, 
we next asked if over-expression of this polyQ-rich region could also alter Htt103Q 
aggregation.  These experiments were carried out in conjunction with the full length 
Cbk1 protein to ensure that the Cbk1 polyQ-rich domain exhibited similar behaviors.  
Interestingly, over-expression of both full length Cbk1 and Cbk1(1-326) localized to a 
perinuclear foci when expressed individually (Figure 3.6B).  This was reminiscent of 
Rnq1 foci that form when over-expressed, however, elevation of Rnq1 causes a growth 
defect [13] where Cbk1 over-expression does not (Figure 3.1A).  When Cbk1 or the 
polyQ-rich domain was expressed along with Htt103Q, the Htt103Q shifted from 
amorphous looking aggregates speckled throughout the cytosol, to co-localize at the 
perinuclear foci with Cbk1 (Figure 3.6B).  These data suggest that the polyQ rich region 
of Cbk1 interacts with Htt103Q, which mediates cytoprotective accumulation of Htt103Q 
in a distinct foci. 
3.3.5 A short proline-rich stretch in the Pop2 polyQ domain is required for impact 
upon Htt103Q toxicity and aggregation 
 Like Cbk1, elevation of Pop2, a subunit of the Ccr4/Not complex, alters Htt103Q 
aggregation and is not essential.  A similar structure/function analysis (Figure 3.7A) 
revealed that the N-terminal polyQ-rich region of Pop2 (Pop2(1-159)) also is necessary to 
suppress Htt103Q toxicity (Figure 3.7B).  The 12 amino acids at the C-terminus of the 
Pop2 polyQ domain are enriched in proline residues (Figure 3.7A).  Since addition of a 
poly-proline region to the Htt103Q construct renders it benign [56,57], we asked whether 
the proline rich region at the end of Pop2(1-159) acts in similar manner.  Excitingly, this 
indeed appears to be the case, as expression of Pop2(1-147) was unable to suppress 
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Htt103Q toxicity.  Proline-rich residues 148-159 of Pop2 were not sufficient to alleviate 
toxicity without the polyQ-rich region, however, as expression of Pop2(148-443) was 
unable to suppress Htt103Q toxicity.  In order to determine if there was a correlation 
between toxicity suppression and a change in Htt103Q aggregation, we monitored the 
aggregation pattern of Htt103Q during co-expression with Pop2.  Expression of full 
length Pop2 or Pop2(1-159) caused Htt103Q to shift from the amorphous looking 
speckled punctae throughout the cytosol to distinct perinuclear foci (Figure 3.7C).  
Pop2(1-147) which lacked the short proline rich region, however, was unable to alter 
Htt103Q aggregation (Figure 3.7C).  Unlike over-expressed Cbk1 which formed 
perinuclear foci, each of the Pop2 constructs was expressed in a diffuse pattern 
throughout the cell (Figure 3.7C).   Upon expression of Htt103Q, however, Pop2 and 
Pop2(1-159) did co-localize with Htt103Q in the perinuclear foci (Figure 3.7C). 
   One of the features of Htt103Q aggregation, and a characteristic of amyloid-like 
proteins, is that it forms SDS-resistant protein oligomers.  Over-expression of Cbk1 and 
Pop2(1-159), but not Pop2(1-147) promoted accumulation of Htt103Q into distinct 
perinuclear foci, so we asked if SDS-resistant oligomer formation followed the same 
pattern.   Under expression conditions where over-expressed polyQ-rich protein 
suppressed Htt103Q toxicity, there was an increase in SDS-resistant Htt103Q as 
measured by SDD-AGE (Figure 3.7D).  While Cbk1 and Pop2(1-159) impacted 
aggregation in this manner, expression of Pop2(1-147) again had no effect on Htt103Q.  
Using gel filtration chromatography, we verified that Pop2(1-159) indeed increased the 
pool of high molecular weight SDS-resistant Htt103Q that remained in the stacking 
portion of the SDS-PAGE gel (Figure 3.4B).  Additionally, Htt103Q and Pop2(1-159) co-
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precipitated from the high molecular weight fractions, but not the monomeric fractions 
providing evidence of an interaction or complex containing these proteins (Figure 3.4C). 
This correlation between packaging into foci, elevated SDS-resistant aggregates, 
and suppression of polyQ toxicity is consistent with a mechanism involving protective 
aggregation.  In contrast to Nab3, the polyQ-rich domains of Cbk1 and Pop2, rather than 
the functional domains, alter Htt103Q toxicity and this characteristic correlates with a 
shift in Htt103Q aggregation pattern.   These data suggest that interaction of Htt103Q 
with certain polyQ domains is sufficient to promote protective aggregation.  These results 
were obtained during overexpression of polyQ-rich domains, but Cbk1 and Pop2 are not 
extremely abundant proteins.  Thus, whether or not these endogenous proteins have a role 
in polyQ toxicity remains unclear.  These data, however, serve as an example of how 
polyQ-rich protein domains can buffer toxicity of polyQ expanded Htt. 
3.3.6 Pop2 and Cbk1 alter Htt103Q toxicity and localization in a Sti1-dependent 
manner 
 Not only does overexpression of Pop2 and Cbk1 increase aggregation of Htt103Q, 
but the spatial distribution of Htt103Q is also altered.  Interestingly, another hit identified 
in the screen, Sti1, acts with Hsp70 to promote accumulation of SDS-resistant material, 
including Htt103Q, in a perinuclear quality control center.  Elevation of Sti1 re-directs 
templated Htt103Q to Sti1 induced foci where potentially toxic amyloid-like material is 
sequestered in a cytoprotective manner.  As over-expression of Pop2 and Cbk1 appear to 
act in a similar way and were discovered in the same screen, these polyQ-rich proteins 
may fall within the same Sti1-dependent protective aggregation pathway.  Thus, we 
tested whether or not Pop2 and Cbk1 could still function as toxicity suppressors in the 
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absence of Sti1.  While each of these proteins suppressed Htt103Q toxicity to a similar 
extent in a wildtype strain, Pop2 and Cbk1 lost this ability in a Sti1 strain demonstrating 
that suppression of toxicity is Sti1 dependent (Figure 3.8A). 
 Endogenous Sti1 functions as an important component to buffer amyloid-like 
proteotoxicity because deletion of Sti1 decreases Htt103Q aggregation while enhancing 
toxicity, essentially interrupting the protective aggregation pathway.  This change in 
aggregation can be visualized utilizing fluorescence microscopy (Figure 3.8B).  As 
suppression of Htt103Q toxicity by Pop2 and Cbk1 overexpression requires Sti1, we next 
examined Htt103Q aggregation during Pop2 and Cbk1 overexpression in a Sti1 strain.  
Once again, Pop2 and Cbk1 activities were dependent upon the presence of Sti1 as 
Htt103Q was no longer redistributed into distinct foci in the Sti1 strain (Figure 3.8B).  
These data demonstrate a correlation between toxicity and aggregation, and place Pop2 
and Cbk1 upstream of Sti1 in a chaperone facilitated protective aggregation pathway 
(Figure 3.8C).    
3.4 Discussion 
 Here, we identified cellular coping mechanisms for the proteotoxic insult caused 
by expression of a polyQ expanded Htt fragment in yeast.   Over-expression of Nab3, 
Pop2, and Cbk1 each individually suppress toxicity of both cytosolic and nuclear 
localized forms of Htt103Q.  Each of these proteins contains a polyQ-rich domain that 
appears to be responsible for interactions with Htt103Q, yet the outcome of such 
interactions differs for the respective suppressors.  Htt103Q appears to inactivate Nab3, 
because only fully functional Nab3 suppresses Htt toxicity.  In contrast, the ectopic 
expression of just the polyQ-rich regions of Pop2 and Cbk1, in the absence of their 
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functional domains, is sufficient to suppress Htt103Q toxicity which correlates with a 
spatial redistribution of Htt103Q to perinuclear foci.  Although Pop2 and Cbk1 appear to 
alter Htt103Q aggregation by different mechanisms, polyQ-domain dependent 
suppression of Htt toxicity was dependent upon the Hsp70 co-chaperone Sti1.  Sti1 
functions in spatial quality control to organize amyloid-like protein assemblies into 
benign perinuclear protein quality control compartments.  Thus, cytotoxicity of polyQ 
proteins is associated with inactivation of essential proteins that contain a polyQ-rich 
region, but can also be buffered via interactions with polyQ-rich proteins.  This leads to 
the partitioning of Htt103Q to an Hsp70 chaperone dependent pathway that mediates 
protective protein aggregation. 
Nab3 is an essential nuclear protein that, when a fully functional form is 
overexpressed, can suppress Htt toxicity without altering Htt aggregation.  Htt103Q and 
Nab3 co-localize in the nucleus, so Htt103Q appears to inactivate Nab3, thereby causing 
proteotoxicity.  Inactivation of essential proteins by Htt103Q occurs with a number of 
transcription factors [25,26,58], and the identification of Nab3 as a target suggests the 
Nrd1 complex is an RNA processing machine that is negatively impacted.  Other RNA 
binding proteins have also been identified in aggregates that contain toxic forms of Htt, 
so polyQ expanded Htt appears to cause proteotoxicity by inactivation of multiple targets 
[38,59].  We observed Nab3 and Htt103Q-NLS co-localize in nuclear punctae, thus, it 
appears that sequestration of Nab3 into Htt103Q-NLS aggregates can titrate Nab3 away 
from its essential function in the Nrd1 complex.  Consistent with these data, Nab3 was 
also identified as a polyQ expanded Htt interacting protein in a recent mass spectrometry 
screen [53].  Interactions between Nab3 and Htt103Q-NLS may occur through the Q-
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domain because this region is required for Nab3 to be functional.    The essential 
importance of the Nab3 polyQ domain is illustrated by our observation that a Nab3 
construct lacking this domain is unable to suppress the lethal phenotype resultant from 
depletion of Nab3 and also is unable to suppress Htt103Q-NLS toxicity.  Since only 
overexpression of a functional form of Nab3 can suppress Htt103Q-NLS toxicity and 
there is no change in Htt103Q-NLS aggregation, restoration of functional Nab3 available 
to act in the Nrd1 complex is likely to be the mechanism for proteotoxicity suppression. 
Approximately 1-3% of eukaryotic proteomes contain proteins with a polyQ 
stretch of at least 5 residues [60,61].  Some of these polyQ stretch proteins are capable of 
interacting with the expanded polyQ domains of disease proteins [6,27,42,43,53,62,63], 
and in most cases such interactions seem to have negative outcomes on protein function 
and cell viability [6,7,43,62,63].  In one instance, interaction between Htt103Q and 
cellular proteins appears to seed formation of toxic Htt103Q [13,24,40,50,64].  Over-
expression of Pop2 and Cbk1 promotes the assembly of Htt103Q into benign SDS-
resistant assemblies, thus, these proteins fall into a unique category of polyQ containing 
proteins which have a positive impact on disease related polyQ.  Why there are both 
positive and negative outcomes of Htt interaction with polyQ protein neighbors remains 
unclear, yet there are several scenarios that could explain these differences.  Flanking 
sequences of the polyQ proteins have a profound effect upon polyQ toxicity and 
aggregation [56,57,65].  Over-expression of the polyQ domain of Pop2 can direct 
Htt103Q to a perinuclear foci, but only if a short proline-rich stretch following the Pop2 
polyQ region is present.  Interestingly, the polyQ stretch in Htt exon 1 is followed by a 
poly-proline stretch, and addition of the this stretch to Htt103Q (in cis) or to Htt25Q (in 
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trans) serves to detoxify Htt103Q in yeast [56,57,66].  Reduced toxicity correlates with 
accumulation of Htt103Q at a perinuclear location which corresponds with spindle pole 
body markers [50,56].  Thus, elevated levels of Pop2 may serve a similar function by 
targeting the Htt103Q to a benign quality control center as a result of the proline-rich 
stretch.   
In addition to flanking regions, subtle differences within the polyQ domains 
themselves may also impact how they affect Htt103Q toxicity.  In this case, the nature of 
the polyQ domain may alter the strength of the interaction or the conformation of 
Htt103Q, which in turn would dictate the amount of templated material and available 
surfaces that can form aberrant interactions.  For example, proline stretches not only 
target Htt103Q to a benign subcellular location, but also can affect Htt conformation 
[65,67,68].  Thus, the proline rich region of Pop2(1-159) might be stabilized in an 
alternate conformation as compared to Pop2(1-147) which lacks the proline rich stretch.  
The conformational shift may change the ability of the protein to interact with Htt103Q 
as Pop2(1-159) is found in perinuclear foci with Htt while Pop2(1-147) is not.    
In the context of the polyQ-rich proteins presented here, what might these subtle 
differences in polyQ domains look like?  Nab3, Cbk1, and Pop2 each contain polyQ-rich 
regions, but little else is similar between these proteins as seen in their alignment.  Nab3 
contains multiple prolines and other nonpolar residues interspersed throughout the many 
short polyQ stretches, while these residues mainly follow 2 polyQ tracts in Pop2.  Cbk1 
has two longer polyQ stretches separated by a region rich in polar residues such as 
glutamines, asparagines, and serines, and these are interspersed with hydrophobic 
residues.  While overexpressed Pop2 only accumulates in perinuclear foci with Htt103Q, 
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overexpressed Cbk1 appears in foci there even in the absence of Htt103Q.  Both Pop2 
and Cbk1 were identified as aggregation prone candidate prion domain containing 
proteins in a bioinformatics screen, but Cbk1’s composition resembled known yeast 
prions such as Rnq1 more than Pop2 [48].  Htt103Q only becomes toxic to yeast when 
Rnq1 is in its prion conformation, [RNQ+]/[PIN+], as this templates Htt103Q, allowing 
entry into the amyloid-like aggregation pathway [6,64].  Importantly, Rnq1 over-
expression is toxic in a [RNQ+] prion background [13] while Cbk1 is not.  Although 
Cbk1 appears to have qualities of a prion protein such as Rnq1, its sequence is distinct 
because Cbk1 contains several polyQ tracts, not just an enrichment in glutamines and 
asparagines.  Thus, elevated levels of Cbk1 promote formation of protective perinuclear 
foci where it appears to act as a sink to sequester otherwise toxic Htt103Q.  This 
interaction and sequestration may be based on its affinity for both itself and polyQ 
expanded Htt, and possibly interfering with Rnq1:Htt103Q interaction. 
Cbk1 and Pop2, when over-expressed, both alter Htt103Q aggregation and 
toxicity albeit by different mechanisms which may be sequence, conformation, or 
targeting based.  The outcome in both cases, however, is protective aggregation of 
Htt103Q and is dependent upon the Hsp70 co-chaperone Sti1.  Pop2 and Cbk1 suppress 
toxicity by acting through a chaperone dependent spatial quality control pathway to drive 
accumulation of proteotoxic Htt103Q in a benign location.  In related studies, we 
demonstrated that elevated Sti1 induces formation of perinuclear foci containing 
amyloid-like material such as Htt103Q (chapter 2).  Elevated levels of Sti1 suppress 
Htt103Q toxicity while deletion of the co-chaperone exacerbates toxicity and inhibits 
SDS-resistant oligomer formation.  These activities are facilitated by the Hsp70/Hsp40 
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machinery which also acts much earlier in the amyloid-like aggregation pathway to 
prevent entry and stimulate refolding of client proteins (Figure 3.8C).  Interestingly, 
Pop2, Cbk1, and Sti1 were all discovered in the same screen, and Pop2 and Cbk1 over-
expression are unable to promote protective aggregation in the absence of Sti1.  These 
observations place the polyQ neighbors of Htt103Q upstream of Sti1 in a chaperone 
dependent facilitated aggregation pathway (Figure 3.8C).  Interaction of Htt103Q with a 
subset of polyQ proteins may impact partitioning of a potentially toxic species towards a 
chaperone dependent pathway to buffer toxicity (Figure 3.8C).   Increased levels of 
components in this spatial quality control pathway promote packaging of Htt103Q into 
perinuclear foci.   
Altogether, there is a complex relationship between polyQ containing proteins 
where Htt103Q can interfere with normal function of certain polyQ proteins, and other 
polyQ proteins can interfere with toxicity of Htt103Q.  A chaperone dependent pathway 
for protective aggregation regulates spatial quality control of proteotoxic polyQ proteins.  
Variations in the relative abundance of components within this polyQ interaction network 
as well as chaperones in a facilitated aggregation pathway may occur from cell type to 
cell type, as well as within a certain cell population over time.  Further studies will better 
define this complex interaction network and how it impacts mechanisms for protective 
packaging and aggregation of polyQ disease proteins.  
3.5 Methods 
Strains and plasmids 
Yeast strains and plasmids used in this study are listed in Supplemental tables 2 and 3.  
All strains harbored Rnq1 in its [RNQ+] prion form unless otherwise indicated.  The 
 88
generation of isogenic [rnq-] strains was accomplished via sequential passage of cells on 
plates containing 3mM guanidinium-HCl.  Plasmid transformation into yeast was 
performed using a lithium acetate method as described previously [13].  Yeast cell culture 
was carried out in synthetic media containing the appropriate amino acids for selection of 
auxotrophic markers.  The Htt25Q and Htt103Q (both with and without the NLS) 
integration strains were generated as described previously (MBoC Sti1 paper).  The Htt 
construct used in these studies consisted of the first 17 amino acids of Htt exon 1 
followed by 25 or 103 glutamine residues, and lacking the proline-rich region.  It also 
contained an N-terminal FLAG tag and a C-terminal GFP tag.  During microscopy and 
Western blot experiments, expression of Htt was induced from the galactose promoter 
with 2% galactose for 4 h.  Cbk1-mRFP constructs and Nab3-mRFP were all expressed 
from a CUP1 promoter induced with 100uM CuSO4 for 5 h.  Each of the remaining 
suppressor constructs were expressed constitutively from their endogenous promoters.  
Rnq1-GFP was also expressed from a CUP1 promoter but no additional copper was 
added to the media in order to see low level overexpression. 
High copy screen for toxicity suppressors 
The Htt103Q-NLS integration strain was transformed with a 2µ yeast expression library 
[69].  Plasmids in this library carried a 5-10 Kb fragment of genomic DNA.  
Transformations were plated on synthetic media containing 2% galactose to induce 
expression of the toxic Htt103Q-NLS construct.  Colonies which were able to grow under 
these conditions were isolated and screened using 5-FOA.  This step was to ensure that 
isolates were not able to grow under toxic conditions due to a mutation.  A plasmid 
rescue was carried out on each colony which exhibited plasmid dependent growth.  These 
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plasmids underwent a sequencing reaction to determine the fragment of DNA which was 
able to suppress Htt103Q-NLS toxicity.  Numerous gene regions (which were not just the 
same DNA fragment, but had overlapping DNA regions) were found multiple times 
suggesting the screen reached saturation.  ORFS in each suppressor were subcloned into a 
pRS426 plasmid along with approximately 400 bp 5’ and 3’ UTR regions so that the 
protein would be expressed from its endogenous promoter to similar levels as those 
during the original screen. 
Toxicity assays 
Yeast samples were normalized to the same OD600, then 5 fold serial diluted with sterile 
distilled water in a 96-well plate.  Dilutions were plated in 10uL spots on appropriate 
synthetic dropout media.  Most images of yeast grown on glucose were scanned at 48h 
and galactose at 72h.  Htt103Q toxicity was assessed on plates containing 2% galactose, 
and in the case of Cbk1-mRFP constructs, supplemented with 500uM CuSO4.  Control 
growth plates contained 2% glucose. 
Fluorescence microscopy 
Fluorescence microscopy was carried out as described previously [24].  Briefly, cultures 
were fixed with 4% formaldehyde and 0.1M KPO4 pH 7.4, and stored in 0.1M KPO4 pH 
7.4 with 1.2M sorbitol. Cells were then permeabilized with 0.1% Triton and stained with 
0.5ug/mL DAPI.  An Olympus IX81 motorized inverted fluorescence microscope paired 
with Metamorph software was used to collect images.  Micrographs were merged and 
processed using ImageJ (NIH) and Photoshop (Adobe). 
Nab3 depletion 
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The Nab3-TetR strain shuts down expression of Nab3 upon addition of doxycycline to 
the growth medium.  This strain was transformed with the indicated plasmids, and 
colonies were expanded in liquid culture.  At mid-log phase growth, 10 ug/mL 
doxycycline was added to the media.  Samples were taken at the indicated timepoints 
starting at time of drug addition (T=0) out to 20 h post doxycycline.  Samples were lysed 
and run on SDS-PAGE followed by Western blotting for endogenous Nab3.   
Western blotting  
Lysates were prepared from pellets of yeast by either mechanical disruption via 
mechanical disruption (for SDD-AGE, co-IP, and gel filtration) as described previously 
[13,24] or an alkali lysis method as described previously [70].  When using mechanical 
disruption, the lysis buffer used was 0.1% Triton X-100, 75mM Tris pH7.4, 150mM 
NaCl, 1mM EDTA, 1mM PMSF, and Sigma protease inhibitor cocktail.  Standard 
separation techniques were used to analyze lysates via SDS-PAGE.  Protein was 
transferred to nitrocellulose for 75-90 min at 110V, and probed using the indicated 
antibodies.  Antibodies used in this study are listed in Supplemental Table 4.   
SDD-AGE 
Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) was carried out as 
described previously [13].  Briefly, Htt103Q was induced for 4 h in cells expressing 
either empty vector, or the indicated toxicity suppressor under control of their respective 
endogenous promoters.  Samples were collected, lysed, and normalized (DC protein 
assay kit; Bio-Rad) and equivalent amounts of total protein were loaded on a standard 
SDS-PAGE gell or into a 1.4% agarose gel containing 0.1% SDS.  The agarose gel was 
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run at 90-100V for approximately 2h, then transferred to PVDF at 12V for 15h and 
Western blotting was carried out.   
Gel filtration chromatography and co-immunoprecipitation 
Cell lysates were prepared via mechanical disruption using the lysis buffer listed above.  
A 500uL loop was loaded with lysates at a concentration of 7 mg/mL total protein which 
was then injected through a sephacryl S-200 gel filtration column (GE Healthcare) at a 
rate of 0.25 mL/min.  Fractions of 1 mL were collected and run on a 10% SDS-PAGE 
gel, followed by standard Western blotting.  For co-IP from column fractions, a 400uL 
aliquot or the indicated fractions were incubated with anti-GFP (to IP the Htt103Q) 
followed by incubation with a 50/50 Protein G bead slurry.  After the beads were washed 
with lysis buffer, they were resuspended in sample buffer and boiled for 10 min prior to 
loading on a 10% SDS-PAGE gel, followed by Western blotting.  Pop2(1-159)-mRFP 
was detected using polyclonal anti-RFP antibody and Htt103Q was detected using 
polyclonal anti-YFP (C. Beckers).   
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3.7 Tables and Figures 
Table 3.1 Genomic fragements that suppress Htt103Q-NLS toxicity 
Gen. fragment # gene biological process polyQ rich Null 
1 STI1 protein folding, Hsp90 No viable 
  CIN5 RNA pol II transcription factor activity No viable 
2 POP2 deadenylation, CCR4/NOT complex Yes viable 
  BRE5 Ubiquitin protease cofactor, deubiquitination No viable 
3 CBK1 Ser/Thr protein kinase Yes viable 
YGP1 Response to nutrient/stress No viable 
ASI2 
ubiquitin-dependent protein catabolic 
process No viable 
  PGA1 mannosyltransferase activity No inviable 
4 GUP2 glycerol transport No viable 
COA2 Cytochrome oxidase assembly factor No viable 
  NAB3 pol II regulation Yes inviable 
5 ZDS2 transcriptional silencing No viable 
YML108W unknown No viable 
PML39 mRNA export from nucleus No viable 
URA5 pyrimidine biosynthesis No viable 
SEC65 protein targeting to ER No inviable 
MDM1 mito. Inheritance, nuc migration No viable 
  NUP188 import and export from nucleus Yes viable 
6 SCD5 actin cytoskelton organization Yes inviable 
  PDR10 ABC transporter No viable 
7 SUL2 sulfate transport No viable 
NYV1 vesicle fusion No viable 
GIS3 unknown No viable 
  IOC2 chromatin remodeling Yes viable 
8 BUD22 bud site selection No viable 
ERG5 ergosterol biosynthetic process No viable 
SOK2 pseudohyphal growth, transcription factor Yes viable 
  SPO20 ascospore-type prospore formation No viable 
9 YHR122w unknown, required for chromatid cohesion No inviable 
EPT1 phosphatidylethanolamine synthesis No viable 
NDT80 Transcription factor No viable 
YHR126c unknown No viable 
YHR127w mitotic spindle elongation No viable 
FUR1 pyrimidine salvage No viable 
  ARP1 nuclear migration No viable 
10 SEC3 transport, vesicle fusion No inviable 
NTF2 protein import into nucleus No inviable 
YER010C unknown No viable 
  TIR1 response to stress No viable 
11 SOK1 cAMP mediated signaling No viable 
TRP1 tryptophan biosynthesis No viable 
GAL3 galactose metabolism No viable 
  SNQ2 ABC transporter, response to drug No viable 
12 MIG1 transcription factor, glucose repression No viable 
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Figure 3.1. Genomic fragments from high copy screen suppress Htt103Q-NLS 
toxicity 
(A) Genomic fragments (GF) 1 through 12 suppress Htt103Q-NLS toxicity as monitored 
by growth assay plated in 5-fold dilutions on galactose containing media.(B) Impact of 
GF1-12 upon Htt103Q-NLS expression levels as monitored by Western blot.  (C) Impact 
of GF1-12 upon aggregation of Htt103Q-NLS as monitored by fluorescence microscopy.  
Bar graph indicates percent of cells with Htt103Q-NLS found in intranuclear foci.  Each 
bar indicates the average ± standard deviation of at least 100 cells counted in at least 3 
different experiments.  Cultures for Western blotting and microscopy were obtained by 
inducing Htt103Q-NLS with 2% galactose for 4-5 h.
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Figure 2. PolyQ-rich proteins suppress Htt103Q-NLS and Htt103Q toxicity 
(A) Diagram of polyQ-rich screen hits.  Numbers represent amino acids.  N- or C-
terminal poly Q-rich regions and functional domains are indicated.  Further information 
is shown in supplemental Figure 1.  (B) Pop2, Cbk1, and Nab3 suppress growth defect 
associated with Htt103Q-NLS and Htt103Q.  Growth assays were plated in 5-fold 
dilutions on glucose (-Htt) or galactose (+Htt).  Western blot indicates Htt expression 
levels at 4 h galactose induction with indicated proteins co-expressed.  (C) Pop2 and 
Cbk1 but not Nab3 alter Htt103Q-NLS and Htt103Q aggregation as monitored by 
fluorescence microscopy.  Nuclei were visualized with DAPI staining.  (D) Toxicity 
associated with Rnq1 over-expression is unaffected by screen hits.  Growth assays were 
plated in 5-fold dilutions on glucose (-Rnq1) or galactose (+Rnq1).  Endogenous Rnq1 is 
present in a [RNQ+] prion state in this experiment.  (E) Pop2 does not alter Rnq1 
localization or prion status.  [RNQ+] prion status was monitored via aggregation of 
Rnq1-GFP expressed from Cup1 promoter at basal levels of copper in media.  Pop2, 
Cbk1, and Nab3 were expressed from high copy plasmids under control of their 
endogenous promoters in each experiment.
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Figure 3.3 PolyQ-rich protein domain details 
(A) Diagram of polyQ-rich proteins.  Numbers indicate amino acid residues.  (B) 
Sequences of polyQ-rich regions in Nab3, Pop2, and Cbk1.  (C) ClustalW2 alignment of 
sequences from (B).  Color legend is indicated. 
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Figure 3.4 Nab3 is depleted by doxycycline and the polyQ-rich region of Pop2 
promotes Htt103Q aggregation 
(A) Doxycycline treatment inhibits expression of Nab3 as monitored by Western blot.  
(B-D) Impact of Pop2(Q) upon Htt103Q aggregation as monitored by size exclusion 
chromatography.  Samples were prepared as indicated in the methods from cultures 
expressing (B) Htt103Q alone, (C) Pop2(Q) alone, or (D) both Htt103Q and Pop2(Q).  
(E) Interaction of Pop2(Q) with high molecular weight Htt103Q material as monitored by 
co-IP.  Htt103Q was precipitated from column fractions indicated. 
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Figure 3.5 Overexpression of Nab3 must be functional for Htt103Q-NLS toxicity 
suppression 
(A) Nab3 requires both the polyQ-rich region and a functional RNA recognition motif to 
complement Nab3 deletion.  Growth assays were plated in 5-fold dilutions on glucose 
plates in the presence or absence of 10ug/mL doxycycline which inhibits Nab3 
expression.  Western blots indicate expression levels of Nab3 constructs each of which 
are under control of the endogenous Nab3 promoter.  (B) Over-expression of non-
functional Nab3 does not suppress Htt103Q-NLS toxicity as monitored by growth assays 
plated in 5-fold dilutions.  (C) Nab3-mRFP co-localizes with Htt103Q-NLS in the 
nucleus and in intranuclear foci as monitored by fluorescence microscopy.  Nuclei were 
visualized with DAPI staining.  Nab3(1-567) lacks the C-terminal polyQ rich region of 
the protein.   
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Figure 3.6 The polyQ-rich region of Cbk1 alters Htt103Q toxicity and aggregation 
(A) Impact of indicated Cbk1 truncations or mutations upon Htt103Q toxicity as 
monitored via growth assays plated in 5-fold dilutions.  Cbk1(1-326) is the polyQ-rich 
region of the protein, and Cbk1(327-756) lacks this region.  (B) Cbk1-mRFP and 
Cbk1(1-327)-mRFP co-localize with Htt103Q in distinct foci.  Cbk1 constructs were 
expressed from a copper inducible promoter induced with 100uM CuSO4 for 5 h total and 
Htt103Q was induced with 2% galactose for 4 h total.  Nuclei were visualized with DAPI 
staining.   
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Figure 3.7 A short proline-rich stretch in the Pop2 polyQ domain is required for 
impact upon Htt103Q toxicity and aggregation 
(A) A diagram illustrating the constructs utilized in these experiments and the sequence 
of the polyQ domain.  The proline-rich region of the Pop2 polyQ domain is highlighted.  
Numbers indicate amino acid residues. (B) Only full length Pop2 and Pop2(1-159) 
suppress Htt103Q toxicity.  Expression of Pop2 constructs was monitored by Western 
blot detection using an anti-RFP antibody.  (C) Pop2 lacking the proline-rich region is 
unable to alter Htt103Q aggregation as monitored by fluorescence microscopy.  Nuclei 
were visualized with DAPI staining.  (D) Pop2(1-159) and Cbk1 increase SDS-resistant 
Htt103Q aggregation as monitored by SDD-AGE and Western blot analysis.  Pop2 and 
Cbk1 were expressed from high copy plasmids under control of their endogenous 
promoters.  Htt103Q was induced with 2% galactose for 4 h. 
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Figure 3.8 Cbk1 and Pop2 act in a Sti1-dependent manner 
(A) Impact of Sti1 deletion upon Pop2 and Cbk1 ability to suppress Htt103Q toxicity.  
Growth assays were plated in 5-fold dilutions on glucose (-Htt) or galactose (+Htt).  (B) 
Impact of Sti1 deletion upon Pop2 and Cbk1 ability to alter Htt103Q aggregation.  (C) 
Model for Htt103Q benign aggregate assembly. 
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